

# VALENTIN FUSTER, MD, PHD



**Address:** The Mount Sinai Medical Center  
One Gustave L. Levy Place, Box 1030  
New York, NY 10029-6574

**Date of Birth:** January 20, 1943

**Place of Birth:** Barcelona, Spain

**Education:**

1954-1961 B.S. Colegio Jesuitas, Barcelona, Spain (Baccalaureate)  
1961-1967 M.D. Faculty of Medicine, Barcelona University, Barcelona, Spain  
1971 Ph.D. University of Edinburgh, Edinburgh, Scotland

**Postdoctoral Training:**

**Internship, Residencies, and Fellowships:**

1967-1968 Internship (Straight Medical), Hospital Clinico, Barcelona, Spain  
1968-1971 Research Fellow in Cardiovascular Diseases, Department of Medicine, Royal Infirmary, University of Edinburgh, Edinburgh, Scotland  
1971-1972 Resident in Medicine, Mayo Graduate School of Medicine, Rochester, Minnesota

**Licensure and Certification:**

1967 Internal Medicine Licensure, University of Barcelona, Spain  
1970 Educational Council for Foreign Medical Graduates  
1974 Minnesota State Board of Medical Examiners  
1976 Internal Medicine Board Certification  
1977 Cardiovascular Diseases Board Certification  
1982 New York State Medicine and Surgery  
1991 Massachusetts State Medicine and Surgery

**Military Service:**

1966-1968 Spanish Army, Second Lt., Barcelona, Spain; Active Duty - 10 months,

Reserve - 2 years

**Academic Appointments:**

- 1997- Richard Gorlin, M.D./Heart Research Foundation Professor of Cardiology, Mount Sinai School of Medicine, New York, New York
- 1994-1997 Arthur M. and Hilda A. Master Professor of Medicine, Mount Sinai School of Medicine, New York, New York
- 1994 Dean for Academic Affairs, Mount Sinai Medical Center, New York, New York
- 1991-1994 Mallinckrodt Professor of Medicine, Harvard Medical School, Boston, Massachusetts
- 1982-1991 Arthur M. and Hilda A. Master Professor of Medicine, Mount Sinai School of Medicine, New York, New York
- 1981-1982 Professor of Medicine and Cardiovascular Diseases, Mayo Medical School, Rochester, Minnesota
- 1980 Associate Professor of Pediatrics, Mayo Medical School, Rochester, Minnesota
- 1978-1981 Associate Professor of Medicine and Cardiovascular Diseases, Mayo Medical School, Rochester, Minnesota
- 1974-1977 Assistant Professor of Medicine and Cardiovascular Diseases, Mayo Medical School, Rochester, Minnesota

**Hospital Appointments:**

- 2002- Director, The Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, Mount Sinai Medical Center, New York, New York
- 1997- Director, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, New York
- 1994-1997 Director, The Zena and Michael A. Wiener Cardiovascular Institute and Vice-Chairman of Medicine, Mount Sinai Medical Center, New York, New York
- 1991-1994 Chief, Cardiac Unit, Massachusetts General Hospital, Boston, Massachusetts
- 1982-1991 Chief, Division of Cardiology, Mount Sinai Medical Center, New York, New York
- 1975-1982 Consultant in Internal Medicine and Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota

**Awards and Honors:**

- 1967 Prize Diputation of Barcelona: Graduated first in the class of the Medical School of Barcelona (Magna Cum Laude in 20 subjects with honors in 18)
- 1968 Fundacion Juan March Research Fellowship Award M.D. Thesis, University of Barcelona, Magna Cum Laude
- 1969-1971 University of Edinburgh Research Fellowship Award
- 1971 Ph.D. Thesis, University of Edinburgh - Presented in Barcelona, "New Orientation for the Study of Platelet Function - Detection of Platelet Factor 4 Methods and Clinical Relevance"
- 
- 1972-1974 Minnesota Heart Association Grant Award
- 1974 Mayo Clinic - Donald C. Balfour Award for Outstanding Research Achievement
- 1976 Miguel Servet 1<sup>st</sup> International Award for Cardiovascular Research, Madrid,

Spain (to the best investigator from Spain working in a foreign country)  
 1985 The Solomon A. Berson Teaching Award  
 1985 The Simon Dack Award for the Best Teacher (chosen by Cardiology Fellows at Mount Sinai Medical Center)  
 1987 Honorary Member, Argentinean Society of Cardiology  
 1987 Honorary Member, Spanish Society of Cardiology  
 1991 Honorary Member, Venezuelan Society of Cardiology  
 1991 Honorary Member, Peruvian Society of Cardiology  
 1991 Honorary Member, Mexican Society of Cardiology  
 1991 New York Heart Research Foundation 1991 Medical Science Award  
 1991 Outstanding Faculty Physician of the Year, Mt. Sinai School of

#### Medicine

1991 Awarded the 1992 Andres Bello Medal of Distinction of the Government of Venezuela  
 1991 Distinguished Physician Award, Dept. of Medicine, Mt. Sinai Medical Center, New York  
 1992 Isabel LaCatolica Medal (Encomienda), Awarded by the Spanish Government  
 1992 Honorary Master's Degree, Harvard Medical School  
 1992 The 1992 Distinguished Scientist Gruntzig Award of the European Society of Cardiology  
 1993 Honorary Member, French Society of Cardiology  
 1993 Honorary Member, Ecuatorana Society of Cardiology  
 1993 Fellow of the Royal College of Physicians at Edinburgh  
 1993 The 1993 Award of the Catalan Foundation for Research  
 1993 The 1993 Distinguished Scientist Award, American College of Cardiology  
 1993 The 1993 Lewis A. Conner Distinguished Presidential Lecture, American Heart Association  
 1993 CINE 1993 Golden Eagle Award for the production "Lipids, Plaque Rupture and the Evolution of Coronary Artery Disease," selected for excellence to represent the United States of America in international film and video events abroad  
 1993 Fundacion Fernandez-Cruz Award, Universidad Complutense, Madrid  
 1994 The 1994 Distinguished Bishop Lecture of the American College of Cardiology  
 1994 The 1994 Narcis Monturiol Catalonia Award  
 1994 Doctor Honoris Causa, Universitat Autònoma de Barcelona  
 1994 The 1994 Presidential Lecture of the Cardiac Society of Australia and New Zealand  
 1994 The 1994 Presidential Lecture of the Japanese College of Cardiology  
 1994 The 50<sup>th</sup> Anniversary Presidential Lecture of the Spanish Society of Cardiology  
 1995 Keynote Plenary Address of the 2<sup>nd</sup> International Conference of Nuclear Cardiology, Cannes, France  
 1995 Jacobi Medallion Award, Mount Sinai Alumni Association  
 1995 Award Fundacion Vila Casas, Barcelona, Spain  
 1995 Honorary Member, Vasco-Navarra Society of Cardiology  
 1995 Honorary Member, Colombian Society of Cardiology

1995 NHLBI-Distinguished Speaker-18<sup>th</sup> Ann. National Cholesterol Educational Program

1995 Doctor Honoris Causa, Universitat Autònoma de Barcelona

1995 Co-Chairman, 27<sup>th</sup> Bethesda Conference

1995 Llico Joan d'Alos Award, Barcelona, Spain

1996 The 1996 Presidential Lecture, Canadian Heart Association

1996 46<sup>th</sup> Annual Scientific Sessions of the Maine Affiliate of the American Heart Association Drake Award

1996 Doctor Honoris Causa, Universidad Nacional de Córdoba, Argentina

1996 Doctor Honoris Causa, University of Barcelona, Spain

1996 Principe de Asturias Award of Science and Technology (the highest award to Spanish speaking scientists, given by the son of the King of Spain), Fundacion Principe de Asturias, Oviedo, Spain

1996 Doctor Honoris Causa, Universidad Nacional de Córdoba, Argentina

1996 Jimenez Diaz Research Award (Madrid)

1996 Rivkah Laufer Bikur Cholim Jewish Foundation Doctor of the Year Award

1996 Mount Sinai School of Medicine Excellence in Teaching Award

1996 Globus Award (Mount Sinai Journal of Medicine)

1997-1998 President-Elect, American Heart Association

1997 Honorary Member, Sociedad Espanola de Medicina Intensiva Y Unidades Coronarias

1997 Honorary Member, Fundacio Universal de la Sardana, Barcelona, Spain

1997 Member, Mount Sinai Medical Center Faculty Practice Associates Board of Governors

1997 Doctor Honoris Causa, University of Barcelona, Spain

1997 The Simon Dack Award for the Best Teacher (chosen by Cardiology Fellows at Mount Sinai Medical Center)

1997 American Heart Association Scientific Councils Distinguished Achievement Award

1997 Spanish Society of Cardiology Gold Medal Recipient, Granada, Spain

1998 American Heart Association NYC Affiliate Achievement Award in CV Science and Medicine

1998 The J. Lester Gabilove Award, Mount Sinai Alumni

1998 Member of Honor, National Academy of Medicine, Madrid, Spain

1998 Doctor Honoris Causa, Universidad de Valladolid, Spain

1998 Doctor Honoris Causa, Universidade Federal do Rio de Janeiro, Brazil

1998 Gill Heart Institute Award for Outstanding Cardiovascular Research, Lexington, Kentucky

1998 Spanish Institute Gold Medal (given by Queen Sofia of Spain), New York

1998 Bristol-Myers Squibb Cardiovascular/Metabolic Diseases Nonrestrictive 5 Year Research Grant Award For Excellence

1999 Heart of Gold Award - American Heart Association - NYC Heritage Affiliate

1998-1999 Honorary Member, La Sociedad Mexicana para el Estudio de la Hipertension Arterial

1998-1999 American Heart Association - President

1999-2000 American Heart Association - Past Immediate President

2000 Distinguished Service Award from the American College of Cardiology

2000 The Marquis Who's Who in the World - Millenium Edition

- 2000 Member, Institute of Medicine, National Academy of Science
- 2001 Doctor Honoris Causa, University of Buenos Aires, Argentina
- 2001 American Heart Association – Herrick Award
- 2002 Distinguished Alumni Award, Mayo Clinic Medical School, Rochester, Minnesota
- 2002 University of Miami, Division of Cardiology “The Thinker” Award,
- 2002 Andreas Gruntzig Award of the International Society of Interventionalists (Paris)
- 2002 Doctor Honoris Causa, University of Murcia, Spain
- 2002 Pregoner Festes de la Mercè, Barcelona, Spain
- 2002 “Giovanni Battista Morgagni” Lecture, Rome, Italy
- 2003 Distinguished Career Award, 11<sup>th</sup> ISTH Biennial Awards for Contributions to Hemostasis
- 2003 – 2004 President-Elect – World Heart Federation
- 2003 Hatter Award, Cape Town, South Africa
- 2003 AHA Gold Heart Award, Washington, D.C.
- 2003 Distinguished Career Award, International Society of Thrombosis and Hemostasis, UK
- 2003 Chazov Gold Medal for Exceptional Achievement in Cardiology, St. Petersburg, Russia
- 2003 Chairman, NHLBI SPARK II Meeting, Bethesda, MD
- 2003 AHA/ASA Distinguished Scientist, presented to only 15 scientists who have made major contributions to cardiovascular research in recent years
- 2004 Appointed to Editor-in-Chief, Nature Cardiovascular Medicine Journal
- 2005 Pro Bono Curantium Gold Medal in honor of John Paul II, Krakow, Poland
- 2006 Distinguished Researcher Award, Interamerican Society of Cardiology
- 2006 Honorary member of the Mexican Society of Cardiology

### **Honorary Lectureships**

- 1983 The 1983 Roon Professorship Lecture, San Diego, CA
- 1986 The Joseph E. Walker Professorship Lecture, Kansas City, MO
- 1987 The 1987 David Scharf Memorial Lecture, Lenox Hill Hospital, New York
- 1988 The 1988 Presidential Citation Lectureship of the American College and World Congress of Chest Physicians, Boston, MA
- 1989 The 1989 Pfizer Visiting Professorship in Cardiovascular Medicine, Medical University of South Carolina, Charleston, SC
- 1989 The 1989 Littman Professorship Lecture, Boston, MA
- 1989 The 1989 Hugo Roesler Memorial Lecture, Temple University, Philadelphia, PA
- 1990 The 1990 Carl J. Wiggers Memorial Lecture, The Cleveland Clinic Foundation, Cleveland, OH
- 1990 Theodore S. Zimmerman Memorial Lecture, La Jolla, CA
- 1990 The 1990 Pfizer Visiting Professorship in CV Medicine, Washington, DC
- 1990 1990 Neuton Stern Honorary Lecture, The Univ. of Tennessee, Memphis, TN
- 1990 1990 Max Stein Honorary Lecture, The Brookdale Hospital Medical Center, Brooklyn, NY

- 1990 1990 Paul Dudley White Honorary Lect. American College of Cardiology, New York, NY
- 1991 Honorary Lecture in Honor of the 500<sup>th</sup> Anniversary of the Discovery of America, San Juan, PR
- 1991 The 1991 James B. Herrick Honorary Lecture, American Heart Association, Chicago, IL
- 1991 The 1991 Jesse E. Edwards Honorary Lecture, University of Minnesota
- 1991 The 1991 Pfizer Visiting Professor at the City University of New York, Stony Brook, NY
- 1992 The 1992 Grollman Lecture, University of Virginia
- 1992 The 1992 Henry Neufeld Memorial Lecture, Israel Heart Society, Tel Aviv, Israel
- 1992 The 1992 Distinguished Basic Research Lecture, American College of Cardiology Postgraduate Course, Washington, D.C.
- 1992 Theodore S. Zimmerman Memorial Lecture, La Jolla, CA
- 1992 The 1992 Mayo Clinic Cardiovascular Visiting Professor
- 1992 State of the Art Lecture at the International Congress, King Faisal Hospital and Research Center, Saudi Arabia
- 1992 State of the Art Lecture at the International Paavo Nurmi Symposium, Helsinki, Finland
- 1992 Magistral Lecture, International Society of Cardiovascular Surgery, Seville
- 1992 NHLBI Lecture Honoring Dr. Gardner McMillan, "Future Directions in Atherosclerosis"
- 1992 1992 State of the Art Lecture, International Conference on Interventional Cardiology and Cardiac Surgery, Long Beach, California
- 1992 1992 Gruntzig Memorial Lecture, European Society of Cardiology, Barcelona
- 1993 The Distinguished Fraser Mustard Lectureship, McMaster University, Ontario, Canada
- 1993 The Twentieth Annual Arvilla Berger Lecture, New York State Chapter, American College of Cardiology
- 1993 Lewis A Conner Distinguished Lecture, American Heart Association
- 1993 Second HJC Swan Honorary Lecture, Cedar Sinai Hospital, Los Angeles, California
- 1993 Pfizer Traveling Fellow, Clinical Research Institute of Montreal, Montreal, Canada
- 1993 Distinguished Speaker, The Centre for Cardiovascular Research, Toronto, Canada
- 1994 The Distinguished Bishop Lecture of the American College of Cardiology
- 1994 The RT Hall Lecture of the Cardiac Society of Australia and New Zealand
- 1995 The First Distinguished Lectures in Cardiovascular Medicine - McMaster University (Hamilton Civic Hospitals Research Centre)
- 1995 Keynote Speaker, AHA The Lipid Nurse Task Force, Arlington, Virginia
- 1995 Distinguished Speaker - NHLBI - 10<sup>th</sup> Anniversary National Cholesterol Education Program - Bethesda, Maryland
- 1996 The Fourth Annual Miriam Lemberg Visiting Professorship in Cardiovascular Disease, University of Miami School of Medicine
- 1996 Martin Lowenthal Memorial Lecture, Mountainside Hospital, Montclair, New Jersey

- 1996 Hahnemann University/AOA Chapter Visiting Professorship, Philadelphia, Pennsylvania
- 1996 Distinguished Speaker, 46<sup>th</sup> Annual Scientific Sessions of the Maine Affiliate of the American Heart Association, Bethel, Maine
- 1996 Distinguished Speaker, Symposium Honoring Dr. Henry Blackburn, University of Minnesota, Minneapolis, Minnesota
- 1996 Calabresi Lectureship, Yale University, New Haven, Connecticut
- 1996 Keynote Speaker, 11<sup>th</sup> Annual Meeting American Association of Cardiovascular & Pulmonary Rehabilitation, Baltimore, Maryland
- 1996 State of the Art Plenary Lecture, European Nuclear Medicine Congress, Copenhagen, Denmark
- 1996 Keynote Speaker, 12<sup>th</sup> Annual Cardiovascular Symposium, Hartford Hospital, Hartford, Connecticut
- 1996 Keynote Speaker, 2<sup>nd</sup> Annual Lecture in Thrombosis, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
- 1996 Keynote Speaker, IX Congreso Nacional de la Sociedad Espanola de Arteriosclerosis, Cordoba, Spain
- 1997 The Don C. and George C. Sutton Memorial Lecture in Cardiology, The Evanston and Glenbrook Hospitals, Evanston, IL
- 1997 Bicentennial Professor Lecture, Dartmouth-Hitchcock Med. Sch. , Lebanon, NH
- 1997 Marion Barnhart Plenary Lecture, XVI Congress of the International Society on Thrombosis and Haemostasis, Florence, Italy
- 1997 Keynote Speaker, Los Cursos de Verano de la Fundacion General de la Universidad Complutense, Madrid, Spain
- 1997 XVI Interamerican Congress of Cardiology International Society and Federation of Cardiology Special Lecture, Fajardo, Puerto Rico
- 1997 26<sup>th</sup> Annual Paul Ware Lecture, Saint Vincent Hospital, Worcester, Massachusetts
- 1997 The Distinguished Lecturer of the Spanish Society of Cardiology, Granada, Spain
- 1997 George Herrmann Scholar, The University of Texas Medical Branch at Galveston, Galveston, TX
- 1998 Anna Borun and Harry Borun Foundation Visiting Professor in Cardiology, UCLA School of Medicine, Los Angeles, CA
- 1998 Bloomfield-Arnold Lecture, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH
- 1998 XXIII Lorenzini Annual Lecture, XIII International Symposium on Drugs Affecting Lipid Metabolism, Florence, Italy
- 1998 Robert L. Frye Lecturer, Mayo Clinic, Rochester, MN
- 1998 Laurence H. Green Lecture, Harvard Medical School, The Brigham and Women's Hospital, Boston, MA
- 1998 State of the Art Lecture, 2<sup>nd</sup> International Conference on Coronary Atherosclerosis, Lugano, Switzerland
- 1998 Lockhart B. McGuire, M.D. Memorial Lecture, University of Virginia School of Medicine, Charlottesville, VA
- 1998 Keynote Speaker, 28<sup>th</sup> AHA Michigan Cardiovascular Research Forum, Detroit, Michigan

- 1999 Keynote Address, Plaque stability: an update. John Hopkins School of Medicine, Baltimore, MD
- 1998-2000 Distinguished Scientist Award Honorary Lecture, Sociedade Portuguesa de Cardiologia
- 1999 Keynote Address, The Heart Institute at Medical Center Bayonet Point, Tampa, FL
- Visiting Professor, Emory University, Atlanta, GA
- 1999 Interamerican Society of Cardiology Lecture, Buenos Aires, Argentina
- 1999 Keynote Speaker, "New Advances in Antiplatelet Therapy", Baylor University, Dallas, TX
- 1999 Keynote Address, "New Insights into Thrombogenesis", 1<sup>st</sup> Annual Ronnie Campbell Meeting, Edinburgh, Scotland
- 1999 Keynote Address, Turkish Society of Cardiology, Istanbul, Turkey
- 1999 Richter Lecture, Indiana Heart Institute, Indianapolis, IN
- 2000 Keynote Speaker, John Hopkins Hospital, Baltimore, MD
- 2000 Distinguished Visiting Scientist, Duke University, Durham, NC
- 2000 Fellows Visiting Professor, Krannert Institute of Cardiology, Indianapolis, IN
- 2000 2000 Abbott Lecture, Society of Cardiovascular Anesthesiologists, Orlando, FL
- 2000 4<sup>th</sup> Annual Potiker Professor, Cleveland Clinic
- 2000 The 2000 Robert Reneman CARIM Lecturer, Maastrich University, Netherlands
- 2000 The 11<sup>th</sup> Anniversary Lecturer of the Society for Vascular Medicine & Biology, Toronto, Canada
- 2000 The 2000 Distinguished Lecturer, The University of Western Ontario, Canada
- 2000 Doctor Honoris Causa, University Coruña, Spain
- 2000 Honorary Member Real Academy of Medicine, Valencia, Spain
- 2000 Magistral Lecture, National Congress of Hematology & Thrombosis, Bilbao, Spain
- 2000 Keynote Address, Plaque Stability Symposium, Johns Hopkins, Baltimore, MD
- 2000 Honorary Speaker, Uruguay Society of Cardiology, Montevideo, Uruguay
- 2000 The 2000 Honorary Speaker Ramón y Cajal Foundation & Hospital, Madrid, Spain
- 2000 Keynote Speaker, American University of Beirut, Beirut, Lebanon
- 2001 Keynote Speaker, New York Medical College Medical Student Research Forum, Valhalla, NY
- 2001 Sujoy B. Roy Oration at AIMS, New Delhi, India
- 2001 Keynote Speaker International Summit on Coronary Artery Disease, Mumbai, India
- 2001 Keynote Speaker, Congress of the Latin American Society of Interventionalist Cardiology, Mexico City, Mexico
- 2001 Keynote Speaker, First Annual Louis Albright Symposium, NJ
- 2001 Dean's Lectureship, Philadelphia, PA
- 2001 George C.Griffith Lecture, Los Angeles, CA
- 2001 Mount Sinai School of Medicine Dean's Lecture, New York, NY
- 2001 Grande Memorial Lecture, Barcelona, Spain
- 2001 Michaelides Lecture, Athens, Greece



- 2001 Keynote Speaker, Sociedad Espanola de Cardiologia, Barcelona, Spain
- 2001 Ethica Award Lecture
- 2002 Chapman Lecture, Baylor in Houston, TX
- 2002 Pfizer Visiting Professor, Richmond VA
- 2002 30<sup>th</sup> Annual Master Lecture, Orlando, FL
- 2002 Dr. Nicholson Lecture, Boston, MA
- 2002 4<sup>th</sup> Annual Jay N. Cohn Lecture, Minneapolis, MN
- 2002 Dr. Roman de Sanctis Lecture, Toledo, Spain
- 2002 James T. Willerson Visiting Professor Lecture, Houston, TX
- 2003 Hatter Lecture, Capetown, South Africa
- 2003 Chairman, NHLBI SPARK II Meeting, Bethesda, MD
- 2003 The Henry Barcroft Lecture, Belfast, No. Ireland
- 2003 Hildner Lecture, Boston, MA
- 2003 World Heart Federation Lecture, Toronto, Canada
- 2003 The Neufield Lecture, ISCP Congress, Barcelona, Spain
- 2003 Pfizer Visiting Professor, Stanford, CA
- 2003 KROC Lecture, Charleston, SC
  
- 2003 Keynote Speaker, 4<sup>th</sup> Congress of CIS Assoc. of Cardiology, St. Petersburg, Russia
- 2003 Johns Hopkins Cardiology Grand Rounds, Speaker, Baltimore, MD
- 2004 Thomas W. Smith, MD Memorial Lecture, Keynote Speaker, Boston, MA
- 2004 Mayo Clinic lecture on Valvular Heart Disease, Keynote Speaker, Rochester
- 2004 Beth Israel Cardiology Grand Rounds, Keynote speaker, New York City
- 2004 Beaumont Heart Center, Grand Rounds speaker, Detroit, MI
- 2004 Stanford University Symposium, The Evolving Paradigm for CAD, Keynote Speaker, Stanford, CA
- 2004 Antithrombotic Therapies, Keynote Speaker, Amsterdam, Netherlands
- 2004 SCMR Scientific Sessions/EURO CMR 2004, Keynote Speaker, Spain
- 2004 World Congress, Human Movements and Immigration, Keynote Speaker, Barcelona, Spain
- 2004 St. Barnabas Health Care System Hospital Symposium, New Jersey
- 2005 Keynote Speaker, The Eighth International Kawasaki Disease Symposium
- 2005 Foro de Marcas Renombradas Espanolas, Madrid, Spain
- 2005 First International Symposium on Prevention of Cardiovascular Diseases, Krakow, Poland
- 2005 Cardiovascular Revascularization Therapy, Washington D.C.
- 2005 25<sup>th</sup> Anniversary of the Principe de Asturias
- 2005 Mario R. Garcia-Palmieri Lecture, San Juan, Puerto Rico
- 2005 Dr. E. Torrado Memorial Lecture, Malaga, Spain

**Memberships in Professional Societies:**

- 1972 Society of the Sigma XI
- 1973 International Society on Thrombosis and Haemostasis
- 1973 Member of the Subcommittee on Platelet Nomenclature of the International Committee on Haemostasis and Thrombosis
- 1974 European Society for Clinical Investigation
- 1976 American Heart Association, Council on Thrombosis,

1977 American College of Cardiology, Fellow,  
 1978 Member of the Central Society for Clinical Research  
 1978 American Heart Association, Council on Circulation  
 1981 Research Committee, Minnesota Heart Association  
 1981 Chairman, Cardiovascular Society, Mayo Clinic  
 1982 Medical Committee, Heart Research Foundation, New York  
 1982 American Heart Association, Member of the Executive Committee, Council  
 on Thrombosis,  
 1983-1996 Corresponding Member of the British Cardiac Society  
 1983 Advisory Board, VA Study on Coronary Artery Bypass Surgery and Platelet  
 Inhibitors  
 1983 Educational Committee, New York Heart Association  
 1984 Board of Directors, New York Cardiological Society  
 1984 American College of Cardiology, Residency Review Committee for  
 Subspecialty of Cardiology (Accreditations Council for Graduate Medical  
 Education)  
 1985 American College of Cardiology, Library Committee,  
 1985 National Institute of Health, Monitoring Committee, TIMI Trial  
 1985 Committee Member of the National Conference on Antithrombotic Therapy  
 (American College of Chest Physicians)  
 1986 Member of the Research Council American Heart Association (New York  
 Affiliate)  
 1986 American Society for Clinical Investigation (“Young Turks”)  
 1986 Member of the National Cholesterol Education Committee, National Institute  
 of Health  
 1987 Committee Member of the Subspecialty Board of Cardiovascular Diseases  
 1987 Member of the Board of Directors, New York Heart Association  
 1987 Member of the Subcommittee on von Willebrand Factor of the International  
 Committee on Haemostasis and Thrombosis  
 1987 ACC/AHA, Member of the Committee for Guidelines on Management of  
 Acute Myocardial Infarction  
 1987 Consultant, New York State Advisory Committee on Cardiovascular Diseases  
 1987 Board of Directors, New York Heart Association  
 1988 National Institutes of Health, Monitoring Committee, Saphenous Vein  
 Bypass Graft Disease Prevention  
 1988 American College of Cardiology - Chairman, Library Committee,  
 1988 American College of Cardiology - Member, Educational Program Committee  
 1989 Faculty Member, Lambda Chapter of Alpha Omega Alpha  
 1989 American College of Cardiology - Member, Task Force on Self-Assessment  
 1989 American Heart Association (New York Affiliate) - Chairman, Professional  
 Education Committee  
 1989 Member, Alpha Omega Alpha Honor Medical Society  
 1989 Member, Executive Committee, New York Heart Association  
 1989 Member, Association of Professors of Cardiology  
 1990 Member, Int. Soc. of Cardiovascular Pharmacotherapy  
 1990 Member, European Society of Cardiology  
 1990 Member, Committee on Inter-American Society of Cardiology  
 1991 American College of Cardiology - Member, Credentials Committee

1991-2003 American College of Cardiology – ACCEL, Associate Editor

1991 Fellow, American College of Chest Physicians

1991 American Heart Association, Member of the Scientific Publishing Committee

1991 NHLBI - Chairman, Data Safety and Monitoring Board of Left Ventricular Assist Systems

1991 NHLBI - Member, Cardiovascular Advisory Committee

1992 Advisory Board, United Patient’s Association for Pulmonary Hypertension

1992 Trustee, College of the Atlantic (Bar Harbor, Maine)

1992 Councilor of the Association of University Cardiologists

1992 American Heart Association - Member of the Vascular Lesions Committee

1992 Harvard Medical School, Committee to Develop a Clinician-Teacher Ladder

1992 Member, Committee on Training Cardiovascular Specialists , Association of Professors of Cardiology

1992 Member, Steering Committee of the ECLA2/RAPT Study, Janssen Research Foundation

1992 AHCPR - NHLBI Member, Expert Panel to Set National Guidelines for the Management of Unstable Angina

1992 Member, Executive Committee of the MGH Laser Center

1992 Member, The Massachusetts Medical Society

1993 President, Board of Directors, Vila Medieval of Cardona Foundation (Spain)

1993-1998 American College of Cardiology - Board of Trustees

1993 American College of Cardiology-Co-Chairman, 42<sup>nd</sup> Annual Scientific Session

1993 American College of Cardiology - Chairman, Credentials Committee

1993 Fellow of the Royal College of Physicians, Edinburgh

1993 Member, Thrombosis and Haemostasis Council of the International Society and Federation of Cardiology

1993 American College of Cardiology - Ad Hoc Task Force to Examine a Cardiovascular Policy Institute

1993 American College of Cardiology - Annual Scientific Session Program Committee

1993 American Heart Association - Vice Chairperson, Scientific Publishing Committee

1993 Founding Member, Society for Adult Congenital Cardiac Disease

1993 Association of Professors of Cardiology - Chairman Cardiology-Medicine Relationships

1994 American College of Cardiology, Board of Directors - Institute for the Study of Cardiovascular Medicine

1994-1995 American Heart Association – Fellowship Subgroup D

1994 American Heart Association - Conflict of Interest Review Committee

1994 American Heart Association - Chairman, Scientific Publishing Committee

1994 American Heart Association - Board of Directors

1994 American Heart Association - Chairman of the Committee on Vascular Lesions

1994-2000 American Heart Association, New York City Affiliate, Board of Directors

1994 American Heart Association, Council on Arteriosclerosis Executive Committee, Member

1994 North American Vascular Biology Organization - Founding Member

1994 The Cardiac Society of Australia and New Zealand, Corresponding Member  
 1994 President, Spanish Cultural Association, Boston, Massachusetts  
 1995 American College of Cardiology, Co-Chairman 27<sup>th</sup> Bethesda Conference  
 1995 American Heart Association, Commission of Science Advisory Committee  
 1995 Association of Professors of Cardiology, Task Force on Cardiology Work  
 Force and Fellowship Training  
 1995 NHLBI Hypertrophy and Vascular Reactivity in Blacks (SCOR Application),  
 External Advising and Review Committee  
 1995-1997 American Heart Association (NY City Affiliate) – Chairman’s Round Table  
 1995-1997 American Heart Association (NY City Affiliate) - Nominating Committee  
 1996-1998 American Heart Association – Council Affairs Committee  
 1996 Medical Advisory Board, Med Help International, Inc.  
 1996 Trustee, The Spanish Institute, New York, New York  
 1996 Academic Advisory Committee Member, Pfizer Visiting Professorship  
 Program in Cardiovascular Medicine  
 1996 Founding Member, Society for Cardiovascular Magnetic Resonance  
 1996-2000 NHLBI Member, Advisory Council  
 1996 NHLBI Chairman, Review of SCOR on Molecular Medicine and  
Atherosclerosis  
 1997 Member, CardioFellows Foundation Advisory Board  
 1997 Member, Fundacion Independiente, Madrid, Spain  
 1997 Member, ACC/AHA Joint Officers Committee  
 1997 Member, Subcommittee for the Commemoration of the American College of  
 Cardiology 50<sup>th</sup> Anniversary  
 1997 Member, FPA Advisory Council, Mount Sinai Medical Center  
 1997-1998 American Heart Association - President-Elect  
 1997-1998 American Heart Association -Vice Chairman, Science Advisory and  
 Coordinating Committee  
 1997-1998 American Heart Association - Ex officio Member, Public Affairs Policy  
 Committee  
 1997-1998 American Heart Association - Member, Scientific Sessions Programs  
 Committee  
 1997-1998 American Heart Association - Vice Chairman, Field Operations Coordinating  
 Committee  
 1997-1998 American Heart Association - Member, Nominating & Awards Committee  
 1997-1998 American Heart Association – CVR Executive Committee  
 1997-1998 American Heart Association - Pharmaceutical Roundtable Medical Advisors  
 1997-1998 American Heart Association – Science Advisory and Coordinating  
 Committee  
 1997-1998 American Heart Association – Stroke Executive Committee  
 1997-1998 American Heart Association – CTVS Executive Committee  
 1997-1998 American Heart Association – ATVB Executive Committee AHA  
 President Elect  
 1997-1998 American Heart Association – Basic Science Executive Committee AHA  
 President Elect  
 1997-1998 American Heart Association – CCC Executive Committee AHA President  
 Elect  
 1997-1998 American Heart Association – CVN Executive Committee AHA President

Elect

1997-1998 American Heart Association – Circulation Executive Committee AHA President Elect

1997-1998 American Heart Association – KCVD Executive Committee AHA President Elect

1997-2003 American College of Cardiology - Chair of the Training Directors

1997-1999 American Heart Association – CVDY Executive Committee AHA President

1997-1999 American College of Cardiology - Ex Officio Member of the Physician Workforce Advisory Committee

1997-2000 American Heart Association – EPI Executive Committee AHA Immediate Past President

1997-2001 American Heart Association – Council on Clinical Cardiology

1998-1999 American Heart Association - President

1998-1999 American Heart Association – HBP Executive Committee AHA President

1998-2000 American Heart Association – Executive Committee AHA Immediate Past President

1998 American Heart Association – Science Advisory and Coordinating Committee President

1998-1999 American Heart Association – Budget Committee

1998-2000 American Heart Association – Executive Committee AHA President

1998-1999 American Heart Association – Council Affairs Committee AHA President

1998-2000 American Heart Association – Council on Circulation

1998 Member, Lipid Nurse Task Force

1998 Honorary Member, Sociedad Medica Hispanoamericana de Nueva York

Member, Association of American Physicians

1998-2002 President, Paul Dudley White Society, Massachusetts General Hospital

1999-2000 American Heart Association – Committee on Scientific Councils AHA Immediate Past President

1999-2000 American Heart Association – Executive Committee AHA Immediate Past President

1999-2000 American Heart Association – Science Advisory and Coordinating Committee Immediate Past President

1999-2001 American Heart Association – Task Force on Scientific Sessions in 21<sup>st</sup> Century

1999-2000 American Heart Association – Basic Cardiovascular Sciences Executive Committee AHA Immediate Past President

1999 National Foundation for Advanced Cardiac Surgery, Scientific Board

1999-2004 Joint ACC/AHA Committee on Practice Guidelines - AHA Representative

1999 NIH National Cholesterol Education Program Clinical Guidelines, Member

1999 Advisory Committee Member, The White Book

1999 International Advisory Board Member, XVIII Congress, ISTH

2000 Member, Institute of Medicine, National Academy of Science

2000 The New York Academy of Medicine, Chair Selection Committee

2000-2003 American College of Cardiology – Chair, Cardiology Training and Workforce Committee

2000-2004 Stanley J. Sarnoff Endowment for Cardiovascular Science, Inc., Board of Directors

2000-2003 American College of Cardiology – Task Force on Workforce, AHA

	Representative
2001-2004	American Heart Association (NY City Affiliate) – Member of the Board of Directors
2001	<u>European Society of Cardiology – U.S. Board of Directors and Industry</u>
2001	Association of Professors of Cardiology
2001	Association of University Cardiologists
2001	Co-Chair, XVIII Congress on the International Society of Thrombosis and Haemostasis
2001	Chairman, ACC/AHA/ESC Atrial Fibrillation 1 <sup>st</sup> guidelines by the three organizations
2002	Chairman, GlaxoSmithKline Foundation for Young Investigators
2002	<u>American Heart Association – Strategically Focused Research Task Force</u>
2002-2004	<u>Stanley J. Sarnoff Endowment for Cardiovascular Science, Inc., Strategic Planning Committee</u>
2002–2003	American College of Cardiology – Task Force to develop a Consensus Conference on Workforce: Working Group on Developing a Uniform System of Designating Cardiologists
2003	American College of Cardiology – Development Committee
2003	American Heart Association, New York City Board of Directors, President
2003	Spanish American Medical Dental Society, New York, NY - Honorary Member
2003	Honorary Member, World Innovation Foundation
2003-2004	<u>World Heart Federation - President-Elect</u>
2003-2005	<u>American Heart Association New York – President</u>
2005-2006	<u>World Heart Federation - President</u>

**Editorial Boards: (selected)**

1982	<u>American Journal of Cardiology</u>
1987	<u>Journal of the American College of Cardiology</u>
1988	<u>Circulation</u>
1991	<u>Arteriosclerosis, Thrombosis and Vascular Biology</u>
1992	<u>Consulting Editor, Circulation</u>
1994	<u>Journal of Thrombosis and Thrombolysis</u>
1997	<u>Consulting Editor, Circulation Research</u>
1998	<u>Journal of Cardiovascular Magnetic Resonance</u>
2003	<u>European Heart Journal</u>
2003	<u>Journal of the American College of Cardiology</u>

**Present Research Support - NIH: (NIH funding since 1975)**

NIH HL-61801-01	Noninvasive MRI of Human Vulnerable Plaque (Principal Investigator) 1998-2003
NIH HL-54469-01	SCOR in Hemostatic and Thrombotic Disease-Blood Tissue Factor Activity, Risk Factor and Coronary Disease (Principal Investigator, Project I) 2001-2006
NIH HL-07208-16A1	Multidisciplinary Research Training Grant (Co-Principal Investigator) 1999-2004

## **Bibliography**

### **Refereed Articles**

1. Clarkson AR, MacDonald MK, Fuster V, Cash JD, Robbison JS. Glomerular coagulation in acute ischemic renal failure. *Quart J Med* 1970; 39:585-599.
2. Wright N, Clarkson AR, Brown SS, Fuster V. Effect of poisoning on serum enzyme activities, coagulation and fibrinolysis. *Br Med J* 1971; 3:347-350.
3. Cash JD, Fuster V, Clarkson AR. Preliminary studies on the protamine sulphate precipitation of plasma and serum. *Scand J Haematol* 1971; 13(Suppl):179-181.
4. Bowie EJW, Cooper HA, Fuster V, Kazmier FJ, Owen CA Jr. The diagnoses of intravascular coagulation. *Throm Diath Haemorrh* 1973; 56:137-143.
5. Fuster V, Kazmier FJ, Cash JD, Bowie EJW, Owen CA Jr. Assay of platelet factor 4 in plasma. *Mayo Clinic Proc* 1973; 48:103-106.
6. Fuster V. Platelet kinetics and effect of aspirin in chronically induced intravascular coagulation in dogs. *Thromb Diath Haemorrh* 1974; 60(Suppl):371-376.
7. Didisheim P, Kazmier FJ, Fuster V. Platelet inhibition in the management of thrombosis. *Throm Diath Haemorrh* 1974; 32:21-34.
8. Fuster V, Bowie EJW, Kazmier FJ, Owen CA Jr. Plasma platelet factor IV-like activity reflecting rate of platelet consumption in chronically induced intravascular coagulation in dogs. *Thromb Res* 1974; 4:247-260.
9. Fuster V, Connolly DC, Frye RL, Danielson MA, Elveback LR, Kurland LT. Arteriographic patterns early in the onset of the coronary syndromes. *Br Heart J* 1975; 37(12):1250-1255.
10. Lewis JC, Fuster V, Kottke BA. Thrombocytes in the atherosclerosis-resistant and atherosclerosis-susceptible breeds of pigeon: A comparative ultrastructural study. *Exper and Mol Pathol* 1976; 25:332-343.
11. Didisheim P, Fuster V. Hematological and vascular concepts in relation to stroke. *Clin Neurosurg* 1976; 23:125-139.
12. Fuster V, Danielson MA, Robb RA, Broadbent JC, Brown AL. Quantitation of left ventricular myocardial fiber hypertrophy and of interstitial tissue in human hearts with pressure and volume overload. *Circulation* 1977; 55:504-508.
13. Fuster V, Kottke BA, Bowie EJW, Ruiz CE, Lewis JC. Increase in platelet factor 4-like activity in the initial stages of atherosclerosis in pigeons. *Adv in Exp Med Biol* 1977; 82:225-227.
14. Fuster V, Lewis JC, Kottke BA, Ruiz CE, Bowie EJW. Platelet factor 4-like activity in the initial stages of atherosclerosis in pigeons. *Throm Res* 1977; 10:169-172.
15. Fuster V, Bowie EJW, Brown AL. Spontaneous arterial lesions in normal pigs and pigs with von Willebrand's disease. *Adv in Exp Med Biol* 1977; 82:315-317.
16. Lewis JC, Fuster V, Kottke BA. Spontaneous endothelial cell injury in the intimal sections of atherosclerotic pigeons. *Prog Biochem Pharmacol* 1977; 14:220-224.
17. Fuster V, Bowie EJW, Lewis JC, Fass DN, Owen CA Jr, Brown AL. Resistance to arteriosclerosis in pigs with von Willebrand's disease: Spontaneous and high cholesterol diet

- induced arteriosclerosis. *J Clin Invest* 1978; 61:722-730.
18. Didisheim P, Fuster V. The actions and clinical status of platelet suppressive agents. *Seminars in Hematol Today* 1978; 15(i):55-72.
  19. Fuster V, Bowie EJW, Lewis JC. The von Willebrand pig as a model for atherosclerosis research. *Thromb and Haemostas* 1978; 39:322-327.
  20. Dewanjee MK, Fuster V, Kaye MP, Josa M. Imaging platelet deposition with III Indium-labeled platelets in coronary artery bypass grafts in dogs. *Mayo Clin Proc* 1978; 53:327-331.
  21. Linos A, Worthington JW, O'Fallon W, Fuster V, Whisnant JP, Kurland LT. Effect of aspirin on prevention of coronary and cerebrovascular disease in patients with rheumatoid arthritis. A long-term follow-up study. *Mayo Clin Proc* 1978; 53(9):581- 586.
  22. Fuster V, Bowie EJW. Interaction of platelets with the endothelium in normal and von Willebrand pigs. *Adv Exp Med and Biol* 1978; 102:187-196.
  23. Fuster V. Long-term results of total correction for Tetralogy of Fallot. *Excerpta Medica Int Congress Series* 1978; 470:780-783.
  24. Guiliani ER, Fuster V, Brandenburg RO, Mair DD. The clinical features and natural history of Ebstein's anomaly of the tricuspid valve. *Mayo Clin Proc* 1979; 54:163-173.
  25. Fuster V, Frye RL, Kennedy MA, Connolly DC, Makin HT. The role of collateral circulation in the various coronary syndromes. *Circulation* 1979; 59:1137-1144.
  26. Metke MP, Lie JT, Fuster V, Kaye MP, Josa M. Reduction of intimal thickening in canine coronary bypass vein grafts with dipyridamole and aspirin. *Am J Cardiol* 1979; 43:1144-1148.
  27. Fuster V, Dewanjee NK, Kaye MP, Josa M, Metke MP, Chesebro JH. Noninvasive radioisotopic technique for detection of platelet deposition in coronary artery bypass grafts in dogs and its reduction with platelet inhibitors. *Circulation* 1979; 60:1508- 1512.
  28. Tyce GM, Fuster V, Owen CA Jr, Winkelman LA. Dipyridamole levels in plasma of man and other species. *Res Commun Chem Pathol Pharmacol* 1979; 26:295-508.
  29. Dewanjee MK, Kaye MP, Fuster V, Rao SA. Noninvasive radioisotopic technique for detection of platelet deposition in mitral valve prosthesis and renal microembolism in dogs. *Trans Am Soc Artif Intern Organs* 1980; 26:475-479.
  30. Cunha CLP, Giuliani ER, Fuster V, Seward JB, Brandenburg RO, McGoon DC. Preoperative M-mode echocardiography as a predictor of surgical results in chronic aortic insufficiency. *J Thorac Cardiovasc Surg* 1980; 79(2):256-265.
  31. Fuster V, McGoon DECC, Kennedy MA, Ritter DG, Kirklin JW. Long-term evaluation (12 to 22 years) of open heart surgery for Tetralogy of Fallot. *Am J Cardiol* 1980; 46:635- 642.
  32. Bowie EJW, Fuster V. Resistance to atherosclerosis in pigs with von Willebrand's disease. *Acta Med Scand* 1980; 642(Suppl):121-130.
  33. Fuster V, Chesebro JH, Frye RL, Elveback LR. Platelet survival and the development of coronary artery disease in the young: The effects of cigarette smoking, strong family history, and medical therapy. *Circulation* 1981; 63:546-551.
  34. Fuster V, Chesebro JH. Coronary atherosclerotic disease. The role of platelets and of platelet inhibitor drugs. *Scand J Haematol* 1981; 27(Suppl 38):1-37.
  35. Fuster V, Chesebro JH. Current concepts of thrombogenesis. Role of platelets. *Mayo Clin Proc* 1981; 56:102-112.
  36. Fuster V, Chesebro JH. Pharmacologic effect of platelet inhibitor drugs. *Mayo Clin Proc* 1981; 56:185-195.
  37. Fuster V, Chesebro JH. Platelet-inhibitor drugs in management of arterial thromboembolic and atherosclerotic disease. Present recommendations. (Part III) *Mayo Clin Proc* 1981; 56:265-273.



38. Robertson JS, Dewanjee MK, Brown ML, Fuster V, Chesebro JH. Distribution and dosimetry of 111-Indium labeled platelets. *Radiology* 1981; 140(1):169-176.
39. Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenburg RO, Frye RL. The natural history of idiopathic dilated cardiomyopathy. *Am J Cardiol* 1981; 47:525-531.
40. Holmes DR Jr, Hartzler GO, Smith HC, Fuster V. Coronary artery thrombosis in patients with unstable angina. *Br Heart J* 1981; 45:411-416.
41. Bowie EJW, Fuster V, Fass DN, Owen CA Jr. The role of von Willebrand factor in platelet-blood vessel interaction, including a discussion of resistance to atherosclerosis in pigs with von Willebrand's disease. *Phil Trans R Soc London B* 1981; 294:267-279.
42. Harker LA, Edmunds H, Fuster V. Antithrombotic therapy of artificial organs. *Trans Am Soc Artif Intern Org* 1981; 27:663.
43. Chesebro JH, Fuster V, Elevback LR, Frye RL. Strong family history and cigarette smoking as risk factors of coronary artery disease in young adults. *Br Heart J* 1982; 47(1):78-83.
44. Agarwal K, Wahner HW, Dewanjee MK, Fuster V, Puga FJ, Danielson GK, Chesebro JH, Feldt RH. Imaging of platelets in right-sided extracardiac conduits in humans. *J Nucl Med* 1982; 23(4):342-347.
45. Fuster V, Pumphrey CW, McGoon MD, Chesebro JH, Pluth JR, McGoon DC. Systemic thromboembolism in mitral and aortic Starr-Edwards prosthesis: A long-term follow-up (10-19 years). *Circulation* 1982; 66(Suppl I):157-161.
46. Hynes JK, Tajik AJ, Seward JB, Fuster V, Ritter DG, Brandenburg RO, Puga FJ, Danielson GK, McGoon DC. Partial atrioventricular canal defect in adults. *Circulation* 1982; 66(2):284-287.
47. Vollertsen RS, Fuster V, Conn DL, Luthra HS, McDuffie FC, Bowie EJW, Ilstrup DM. In vivo platelet survival in rheumatoid arthritis. *Mayo Clin Proc* 1982; 57:620-628.
48. Danielson GK, Fuster V. Surgical correction of Ebstein's anomaly. *Ann Surg* 1982; 196:499-504.
49. Beard CM, Fuster V, Elveback LR. Daily and seasonal variation in sudden cardiac death, Rochester Minnesota, 1950-1975. *Mayo Clin Proc* 1982; 57:704-706.
50. Pumphrey CW, Fuster V, Dewanjee MK, Murphy KP, Vlietstra RE, Kaye MP. A new in vivo model of arterial thrombosis: The effect of administration of Ticlopidine and Verapamil in dogs. *Thromb Res* 1982; 28(5):663-675.
51. Fuster V, Fass DN, Kaye MP, Josa M, Zinsmeister AR, Bowie EJW. Arteriosclerosis in normal and von Willebrand pigs: Long-term prospective study and aortic transplantation study. *Circ Res* 1982; 51(v):587-593.
52. Chesebro JH, Clements IP, Fuster V, Elveback LR, Smith HC, Bardsley WT, Frye RL, Holmes DR Jr, Vlietstra RE, Pluth JR, Wallace RB, Puga FJ, Orszulak TA, Piehler JM, Schaff HV, Danielson GK. Platelet inhibitor drug trial in coronary artery bypass operation: Benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein graft patency. *N Engl J Med* 1982; 307:73-78.
53. Badimon L, Fuster V, Dewanjee MK, Romero JC. A sensitive new method of "ex vivo" platelet deposition. *Thromb Res* 1982; 28:237-250.
54. Chesebro JH, Fuster V. Drug trials in prevention of occlusion of aorta-coronary artery vein grafts. *J Thorac Cardiovasc Surg* 1982; 83:90-93.
55. Dewanjee MK, Tago M, Fuster V, Kaye MP. Platelet turnover in aortocoronary femoral vein bypass graft in control and aspirin-dipyridamole-treated dogs: Prevention of early thrombotic occlusion of bypass graft. *Nucl Med & Biol* 1982; 1:898-901.
56. Pumphrey CW, Dewanjee MK, Chesebro JH, Fuster V, Wahner HW. a new method for quantifying human platelet-vascular graft interaction and the effect of platelet inhibitor

- therapy. *Nucl Med & Biol* 1982; 1:895-897.
57. Dewanjee MK, Pumphrey CW, Murphy KP, Fuster V, Kaye MP, Rosemark JA, Chesebro JH. Evaluation of platelet-inhibitor drugs in a canine bilateral femoral graft implant model. *Trans Am Soc Artif Intern Org* 1982; 28:504-509.
  58. Chesebro JH, Fuster V. Platelet inhibitors in coronary artery bypass operations. *N Engl J Med* 1982; 307(23):1453-1454.
  59. Pumphrey CW, Fuster V, Dewanjee MK, Chesebro JH, Vliestra RE, Kaye MP. Comparison of the antithrombotic action of calcium antagonist drugs with dipyridamole in dogs. *Am J Cardiol* 1983; 51:591-595.
  60. Chesebro JH, Fuster V. Platelets and platelet inhibitor drugs in aortocoronary vein bypass operations. *Intern J Cardiol* 1983; 2:511-516.
  61. Pumphrey CW, Chesebro JH, Dewanjee MK, Wahner HW, Hollier LJ, Pairolero PC, Fuster V. In vivo quantitation of platelet deposition on human peripheral arterial bypass grafts using Indium-111-labeled platelets: Effect of dipyridamole and aspirin. *Am J Cardiol* 1983; 51:796-801.
  62. Chesebro JH, Fuster V, Elveback LR, McGoon DC, Pluth JR, Puga FJ, Wallace RB, Danielson GK, Orszulak TA, Piehler JM, Schaff HV. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: Danger of aspirin compared with dipyridamole. *Am J Cardiol* 1983; 51(9):1537-1541.
  63. Dewanjee MK, Fuster V, Rao SA, Forsham PL, Kaye MP. Noninvasive radioisotopic technique for the detection of platelet deposition in mitral valve prostheses and quantitation of visceral microembolism in dogs. *Mayo Clin Proc* 1983; 58:307-314.
  64. Badimon L, Fuster V, Chesebro JH, Dewanjee MK. New "ex vivo" radioisotopic method of quantitation of platelet deposition: Studies in four animal species. *Thromb and Haemost* 1983; 50(3):639-644.
  65. Ambrose JA, Fuster V. Coronary collateral vessels and myocardial protection. *Int J Cardiol* 1983; 3:417-420.
  66. Nishimura RA, Fuster V, Burgert SL, Puga FJ. Clinical features and long-term natural history of the postpericardiotomy syndrome. *Int J Cardiol* 1983; 1:918-921.
  67. Wahner HW, Dunn WL, Dewanjee MK, Fuster V. Survival time and organ distribution of 111In-Oxine-labeled human platelets in normal subjects. *Nucl Med and Biol* 1983; 1:918-921.
  68. Cohen M, Fuster V. What do we gain from the analysis of right ventricular function? *J Am Coll Cardiol* 1984; 3(4):1082-1084.
  69. Chesebro JH, Fuster V, Elveback LR, Clements IP, Smith HC, Holmes DR, Bardsley WT, Pluth JR, Wallace RB, Puga FJ, Orszulak TA, Piehler JM, Danielson GK, Scchaff HV, Frye RL. Effect of dipyridamole and aspirin on late vein graft patency after coronary bypass operation. *N Engl J Med* 1984; 310:209-214.
  70. McGoon MD, Fuster V, McGoon DC, Pumphrey CW, Pluth JR, Elveback LR. Aortic and mitral valve incompetence: Long-term follow-up (10-19 years of patients treated with the Starr-Edwards prosthesis. *J Am Coll Cardiol* 1984; 3(4):930-938.
  71. Dewanjee MK, Tago M, Josa M, Fuster V, Kaye MP. Quantification of platelet retention in aortocoronary femoral vein bypass graft in dogs treated with dipyridamole and aspirin. *Circulation* 1984; 69(2):350-356.
  72. Donadio JV Jr, Anderson CF, Mitchell JC III, Holley KE, Ilstrup DM, Fuster V, Chesebro JH. Membranoproliferative glomerulonephritis: A prospective clinical trail of platelet-inhibitor therapy. *N Engl J Med* 1984; 310(32):1421-1426.
  73. Beard CM, Fuster V, Annegers JF. Reproductive history in women with coronary heart

- disease: A case-control study. *Am J Epidemiology* 1984; 120(1):108-114.
74. Beckett VL, Conn DL, Osmundson PJ, Strong CG, Chao EYS, Chesebro JH, O'Fallon WM, Fuster V. Trial of platelet-inhibiting drug in scleroderma. A double-blind study with dipyridamole and aspirin. *Arthritis and Rheumatism* 1984; 27(10):1137-1143.
  75. Fuster V, Steel PM, Edwards WD, Gersh BI, McGoon MD, Frye RL. Primary pulmonary hypertension: Natural history and the importance of thrombosis. *Circulation* 1984; 70(4):580-587.
  76. Squire A, Goldman ME, Kupersmith J, Stern EH, Fuster V, Schweitzer P. Long-term antiarrhythmic therapy: Problem of low drug levels and patients' non-compliance. *Am J Med* 1984; 77:1035-1038.
  77. Goldman ME, Mindich BP, Teichholz LE, Burgess N, Staville K, Fuster V. Intraoperative contrast echocardiography to evaluate mitral valve operations. *J Am Coll Cardiol* 1984; 4(5):1035-1040.
  78. Fuster V, Lie JT, Badimon L, Rosemark JA, Badimon JJ, Bowie EJW. Spontaneous and diet induced coronary atherosclerosis in normal swine and swine with von Willebrand's disease. *Arteriosclerosis* 1985; 5:67-73.
  79. Cortina A, Ambrose JA, Prieto-Granda J, Moris C, Simarro E, Holt J, Fuster V. Left ventricular function after myocardial infarction. Clinical and angiographic correlations. *J Am Coll Cardiol* 1985; 5(3):619-624.
  80. Ambrose JA, Winters SL, Stern A, Eng A, Teichholz LE, Gorlin R, Fuster V. Angiographic morphology and the pathogenesis of unstable angina pectoris. *J Am Coll Cardiol* 1985; 5(3):609-616.
  81. Hu DCK, Seward JB, Puga FJ, Fuster V, Tajik AJ. Total correction of Tetralogy of Fallot at age 40 years and older: Long-term follow-up. *J Am Coll Cardiol* 1985; 5(1):40-44.
  82. Fuster V, Steele PM, Chesebro JH. Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. *J Am Coll Cardiol* 1985; 5(6):175B-184B.
  83. Steele PM, Chesebro JH, Stanson AW, Holmes DR Jr, Dewanjee MK, Badimon L, Fuster V. Balloon angioplasty: Natural history of the pathophysiologic response to injury in a pig model. *Circ Res* 1985; 57(1):105-112.
  84. Cohen M, Horowitz SF, Machac J, Mindich BP, Fuster V. Response of the right ventricle to exercise in isolated mitral stenosis. *Am J Cardiol* 1985; 55:1054-1058.
  85. Verstraete M, Dejana E, Fuster V, Lapetina E, Moncada JF, Mustard JF, Tans G, Vargaftig BB. An overview of antiplatelet and antithrombotic drugs. *Haemostasis* 1985; 15:89-99.
  86. Riegel N, Ambrose JA, Mindich BP, Fuster V. Isolated aortic stenosis with severe pulmonary hypertension. *Cath Cardiovasc Diag* 1985; 11:181-185.
  87. Mindich BP, Goldman ME, Fuster V, Burgess N, Litwak R. Improved intraoperative evaluation of mitral valve operation utilizing two-dimensional contrast echocardiography. *J Thorac Cardiovasc Surg* 1985; 90:112-118.
  88. Badimon L, Steele P, Badimon JJ, Bowie EJW, Fuster V. Aortic atherosclerosis in pigs with heterozygous von Willebrand's disease: Comparison with homozygous von Willebrand and normal pigs. *Arteriosclerosis* 1985; 5(4):366-370.
  89. Lapeyre AC III, Steele PM, Kazmier FJ, Chesebro JH, Vlietstra RE, Fuster V. Systemic embolism in chronic left ventricular aneurysm: Incidence and the role of anticoagulation. *J Am Coll Cardiol* 1985; 6:1233-1238.
  90. Fuster V, Chesebro JH. Aortocoronary artery vein-graft disease. Experimental and clinical approach for the understanding of the role of platelets and platelet inhibitors. *Circulation* 1985; 72(Suppl V):65-70.
  91. Ambrose JA, Winters SL, Arora RR, Haft JI, Goldstein J, Rentrop KP, Gorlin R, Fuster V:

- Coronary angiographic morphology in myocardial infarction. A link between the pathogenesis of unstable angina and myocardial infarction. *J Am Coll Cardiol* 1985; 6:1233-1238.
92. Cohen M, Edwards WD, Fuster V. Regression in thromboembolic type of primary pulmonary hypertension during 2 1/2 years of antithrombotic therapy. *J Am Coll Cardiol* 1986; 7:172-175.
  93. Ambrose JA, Winters SL, Arora RR, Eng A, Riccio A, Gorlin R, Fuster V. Angiographic evolution of coronary artery morphology in unstable angina. *J Am Coll Cardiol* 1986; 7:472-478.
  94. Fuster V, Chesebro JH. Role of platelets and platelet inhibitors in aortocoronary artery vein graft disease. *Circulation* 1986; 73(2):227-232.
  95. Hirsh J, Fuster V, Salzman E. Dose antiplatelet agents: The relationship among side effects, and antithrombotic effectiveness. *Chest* 1986; 89(2):4S-10S.
  96. Dewanjee MK, Wahner HW, Dunn WL, Robertson JS, Offord K, Fuster V, Chesebro JH. Comparison of three platelet markers for measurement of survival time in healthy volunteers. *Mayo Clin Proc* 1986; 61:327-336.
  97. Meltzer RS, Teichholz LE, Visser CA, Fuster V. Intracardiac thrombi and systemic embolization: The role of two-dimensional echocardiography. *Ann Int Med* 1986; 104:689-698.
  98. Badimon L, Badimon JJ, Galvez A, Chesebro JH, Fuster V. Influence of arterial damage and wall shear rate on platelet deposition. Ex vivo study in a swine model. *Arteriosclerosis* 1986; 6(3):312-320.
  99. Gorlin R, Fuster V, Ambrose JA. Anatomic-physiologic links between acute coronary syndromes. *Circulation* 1986; 74(1):6-9.
  100. Frye RL, Parmley WW, Brundage B, Fortuin N, Fowler NO, Fuster V, Harvery WP, Hurst JW, Joyce JW, Rackley CE, Rapaport E, Reitemeier RJ, Russell RO Jr, Ryan TJ, Saunders DE. Task Force I: Training in clinical cardiology. *J Am Coll Cardiol* 1986; 7(6):1196-1200.
  101. Chesebro JH, Fuster V. Antithrombotic therapy for acute myocardial infarction: Mechanisms and prevention of deep venous, left ventricular, and coronary artery thromboembolism. *Circulation* 1986; 74(Suppl III):1-10.
  102. Chesebro JH, Fuster V. The pathogenesis and prevention of aortocoronary bypass graft occlusion and restenosis after arterial angioplasty: Role of vascular injury and platelet thrombus deposition. *J Am Coll Cardiol* 1986; 8:57B-66B.
  103. Goldman M, Fuster V, Guarino T, Mindich B. Intraoperative echocardiography for the evaluation of valvular regurgitation: Experience in 263 patients. *Circulation* 1986; 74(Suppl I):143-149.
  104. Farhi JJ, Cohen M, Fuster V. The broad spectrum of unstable angina pectoris and its implications for future controlled trials. *Am J Cardiol* 1986; 58:547-550.
  105. Lam JYT, Chesebro JH, Steele PM, Dewanjee MK, Badimon L, Fuster V. Deep arterial injury during experimental angioplasty: Relation to a positive Indium-111 labeled platelet scintigram, quantitative platelet deposition, and mural thrombosis. *J Am Coll Cardiol* 1986; 8(6):1380-1386.
  106. Hjemdahl-Monsen CE, Lewis HD, Cairns J, Chesebro JH, Fuster V. The role of anti-thrombotic therapy in unstable angina, myocardial infarction, and sudden death. *J Am Coll Cardiol* 1986; 8(6):67B-75B.
  107. Vallabhajosula S, Machac J, Goldsmith SJ, Lipszyc H, Badimon L, Rand J, Fuster V. Indium-111 platelet kinetics in normal human subjects: Tropolone versus oxine methods. *J Nucl Med* 1986; 27:1669-1674.

108. Vermynen J, Verstraete M, Fuster V. Role of platelet activation and fibrin formation in thrombogenesis. *J Am Coll Cardiol* 1986; 8(6):2B-9B.
109. Harker LA, Fuster V. Pharmacology of platelet inhibitors. *J Am Coll Cardiol* 1986; 8(6):21B-32B.
110. Chesebro JH, Adams PC, Fuster V. Antithrombotic therapy in patients with valvular heart disease and prosthetic heart valves. *J Am Coll Cardiol* 1986; 8(6):41B-56B.
111. Adams PC, Cohen M, Chesebro JH, Fuster V. Thrombosis and embolism from cardiac chambers and infected valves. *J Am Coll Cardiol* 1986; 8(6):76B-87B.
112. Fuster V, Chesebro JH. Mechanisms of unstable angina. *N Engl J Med* 1986; 315(16):1023-1025.
113. Fuster V, Griggs TR. Porcine von Willebrand's disease. Implications for the pathophysiology of atherosclerosis and thrombosis. *Prog Hemostas and Throm* 1986; 159-183.
114. Galvez A, Badimon L, Badimon JJ, Fuster V. Electrical aggregometry in whole blood from human, pig and rabbit. *Thromb and Haemostas* 1986; 56(2):128-132.
115. Cohen M, Fuster V. Unstable angina: Is it time for more aggressive therapy? *Eur J Cardiol* 1986; 7(12):1014-1015.
116. Adams PC, Lam JYT, Badimon L, Chesebro JH, Fuster V. Interactions of platelets and vessel wall in the development of restenosis after coronary angioplasty. In: Blood in Contact with Natural and Artificial Surfaces. (Eds: Leonard EF, Turitto VT, Vroman). *Annals of the NY Academy of Sciences*, New York, NY, 1987, Volume 516, pp 605-620.
117. Lam JYT, Chesebro JH, Steele PM, Fuster V. Is vasospasm related to platelet deposition? Relationship in a porcine preparation of arterial injury in vivo. *Circulation* 1987; 75(1):243-248.
118. Ambrose JA, Hjemdahl-Monsen CE, Borricco S, Sherman WS, Cohen M, Gorlin M, Gorlin R, Fuster V. Quantitative and qualitative effects of intracoronary streptokinase in unstable angina and non Q wave infarction. *J Am Coll Cardiol* 1987; 9(5):1156-1165.
119. Rand JH, Badimon L, Gordon RE, Fuster V. Distribution of von Willebrand factor in porcine intima varies with blood vessel type and location. *Arteriosclerosis* 1987; 7(3):287-291.
120. Cohen M, Monsen C, Francis X, Sherman W, Ambrose JA, Teichholz LE, Fuster V. Comparison of single plane videodensitometry-based right ventricular ejection fraction in right and left anterior oblique views to biplane geometry-based right ventricular ejection fraction. *J Am Coll Cardiol* 1987; 10:150-155.
121. Goldman ME, Mora F, Guarino T, Fuster V, Mindich BP. Mitral valvuloplasty is superior to valve replacement for preservation of left ventricular function: An intraoperative two-dimensional echocardiographic study. *J Am Coll Cardiol* 1987; 10:567-575.
122. Goldman ME, Guarino T, Fuster V, Mindich B. The necessity for tricuspid valve repair can be determined intraoperatively by two-dimensional echocardiography. *J Thorac Cardiovasc Surg* 1987; 94:542-550.
123. Steele PM, Fuster V, Cohen M, Ritter DG, McGoon DC. Isolated atrial septal defect with pulmonary vascular obstructive disease: Long-term follow-up and prediction of outcome after surgical correction. *Circulation* 1987; 76:1037-1042.
124. Badimon L, Badimon JJ, Rand R, Turitto VT, Fuster V. Platelet deposition on von Willebrand factor deficient vessels: Extracorporeal perfusion studies in von Willebrand's disease swine utilizing native and heparinized blood. *J Lab Clin Med* 1987; 110:634-647.
125. Chesebro JH, Fuster V. The therapeutic challenge of plaque rupture: Value of biochemical markers. *J Am Coll Cardiol* 1987; 10:1005-1006.
126. Adams PC, Fuster V, Badimon L, Badimon JJ, Chesebro JH. Platelet-vessel wall

- interactions, rheologic factors and thrombogenic substrate in acute coronary syndromes: Preventive strategies. *Am J Cardiol* 1987; 60:9G-16G.
127. Badimon L, Badimon JJ, Turitto VT, Fuster V. Thrombosis: Studies under flow conditions. In: Blood in Contact with Natural and Artificial Surfaces. (Eds: Leonard EF, Turitto VT, Vroman). *Annals of the NY Academy of Sciences*, New York, NY, 1987, Volume 516, pp 527-540.
  128. Turitto VT, Weiss HJ, Baumgartner HR, Badimon L, Fuster V. Cells and aggregates at surfaces. In: Blood in Contact with Natural and Artificial Surfaces. (Eds: Leonard EF, Turitto VT, Vroman). *Annals of the NY Academy of Sciences*, New York, NY, 1987, Volume 516, pp 453-467.
  129. Badimon L, Turitto V, Rosemark JA, Badimon JJ, Fuster V. Characterization of a tubular flow chamber for studying platelet interaction with biological and prosthetic materials. Deposition of <sup>111</sup>Indium-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene. *J Lab Clin Med* 1987; 110:706-718.
  130. Badimon L, Badimon JJ, Turitto VT, Fuster V. Role of von Willebrand factor in platelet interaction with an expanded PTFE surface. *Trans Am Soc Artif Intern Organ* 1987; 10:621-625.
  131. Chesebro JH, Lam JYT, Badimon L, Fuster V. Restenosis after arterial angioplasty: A hemorrhheologic response to injury. *Am J Cardiol* 1987; 60:10B-16B.
  132. Badimon L, Badimon JJ, Fuster V. Pared arterial y arteriosclerosis. *Rev Esp Geriatr y Gerontol* 1987;22:39-49.
  133. Badimon JJ, Badimon L, Galvez A, Fuster V. HDL, prostaciclina y arteriosclerosis. *Sangre* 1987; 24:80-83.
  134. Fuster V, Badimon L, Badimon JJ, Chesebro JH. Prevention of thromboembolism induced by prosthetic heart valves. *Seminars in Thrombosis and Hemostasis* 1988; 14:50-58.
  135. Charney R, Leddomado E, Rose DN, Fuster V. Anticoagulation clinics and the monitoring of anticoagulant therapy. *Intern J Cardiol* 1988; 18:197-207.
  136. The Expert Panel: Report of the National Education Program: Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. *Arch Intern Med* 1988; 148:36-69.
  137. Fuster V, Cohen M, Chesebro JH. Usefulness of aspirin for coronary artery disease. *Am J Cardiol* 1988; 61:637-640.
  138. Fuster V, Badimon L, Cohen M, Ambrose J, Badimon JJ, Chesebro JH. Insights into the pathogenesis of acute ischemic syndromes. *Circulation* 1988; 77:1213-1220.
  139. Gorlin R, Fuster V, Ambrose JA. Anatomic-physiologic links between acute coronary syndromes. *Current Views from Circulation: Preludes and Progress/Editorials and Perspectives*. July 1986 - June 1988, pp 2-5.
  140. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro JH. Insights into the pathogenesis of acute ischemic syndromes. *Current Views from Circulation: Preludes and Progress/Editorials and Perspectives*. July 1986 - June 1988, pp 15-24.
  141. Vallabhajosula S, Paidi M, Badimon JJ, Le NA, Goldsmith SJ, Fuster V, Ginsberg HN: Radiotracers for low density lipoprotein biodistribution studies in vivo: Technetium- 99m low density lipoprotein versus radioiodinated low density lipoprotein preparations. *J Nucl Med* 1988; 29:1237-1245.
  142. Ambrose JA, Monsen C, Borrico S, Gorlin R, Fuster V. Angiographic demonstration of a common link between unstable angina pectoris and non-Q wave acute myocardial infarction. *Am J Cardiol* 1988; 61:244-247.
  143. Ambrose JA, Tannenbaum M, Alexopoulos D, Hjemdahl-Monsen CE, Leavy J, Weiss M,

- Borrigo S, Gorlin R, Fuster V. Angiographic progression of coronary artery disease and the development of myocardial infarction. *J Am Coll Cardiol* 1988; 12:56-62.
144. Heras Magda, Chesebro JH, Penny WJ, Bailey KR, Lam JYT, Holmes DR, Reeder GS, Badimon L, Fuster V. Importance of adequate heparin dosage in arterial angioplasty in a porcine model. *Circulation* 1988; 78:654-660.
145. Lam JYT, Chesebro JH, Fuster V. Platelets, vasoconstriction, and nitroglycerin during arterial wall injury: A new antithrombotic role for an old drug. *Circulation* 1988; 78:712-716.
146. Schwinger M, Cohen M, Fuster V. Usefulness of onset of the pulmonary wedge V wave in predicting mitral regurgitation. *Am J Cardiol* 1988; 62:646-648.
147. Cohen M, Charney R, Hershman R, Fuster V. Reversal of chronic ischemic myocardial dysfunction after transluminal coronary angioplasty. *J Am Coll Cardiol* 1988; 12:1193-1198.
148. Weinberger J, Ramos L, Ambrose JA, Fuster V. Morphologic and dynamic changes of atherosclerotic plaque at the carotid artery bifurcation: Sequential imaging by real time B-mode ultrasonography. *J Am Coll Cardiol* 1988; 12:1515-1521.
149. Fuster V, Stein B, Badimon L, Chesebro JH. Antithrombotic therapy after myocardial reperfusion following myocardial infarction. *J Am Coll Cardiol* 1988; 12:78A-84A.
150. Badimon L, Badimon JJ, Turitto VT, Vallabhajosula S, Fuster V. Platelet thrombus formation on collagen type I: A model of deep vessel injury. Influence of blood rheology, von Willebrand factor and blood coagulation. *Circulation* 1988; 78:1431-1442.
151. The TIMI Research Group: Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. *JAMA* 1988; 260:2849- 2858.
152. Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, Doherty J, Read R, Chesler E, Sako Y, Lancaster L, Emery R, Sharma G, Josa M, Pacold I, Montoya A, Parikh D, Sethi G, Holt J, Kirklin J, Shabetai R, Moores W, Aldridge J, Masud Z, DeMots H, Floten S, Haakenson C, Harker LA (Fuster V, Data Monitoring Board). Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy. *Circulation* 1988; 77:1324-1332.
153. Israel DH, Adams PC, Stein B, Chesebro JH, Fuster V. Antithrombotic therapy in coronary vein graft patients. *Clin Cardiol* 1991; 14:283-295.
154. Ip JH, Stein B, Fuster V, Badimon L. Antithrombotic therapy in cardiovascular diseases. Future directions based on pathogenesis and risk. *Ann NY Acad Sci* 1991; 614:289-311.
155. Fuster V, Halperin JL. Left ventricular thrombi and cerebral embolism. *N Engl J Med* 1989; 320:392-394.
156. Cairns JA, Collins R, Fuster V, Passamani ER. Coronary thrombosis. *Chest* 1989; 95:73S-87S.
157. Badimon L, Badimon JJ, Turitto VT, Rand J, Fuster V. Functional behavior of vessels from pigs with von Willebrand's disease: Values of platelet deposition are identical to those obtained on normal vessels. *Arteriosclerosis* 1989; 9:184-188.
158. Badimon JJ, Badimon L, Galvez A, Dische R, Fuster V. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. *Lab Invest* 1989; 60:455-461.
159. Hirsh J, Salzman EW, Harker L, Fuster V, Dalen JE, Cairns JA, Collins R. Aspirin and other platelet active drugs: Relationship among dose, effectiveness, and side effects. *Chest* 1989; 95:12S-18S.
160. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. *Circulation* 1989; 79:657-665.

161. The TIMI Study Group: Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Result of the thrombolysis in myocardial infarction (TIMI) Phase II trial. *N Engl J Med* 1989; 320:618-627.
162. Fuster V, Cohen M, Halperin JL. Aspirin in the prevention of coronary disease. *N Engl J Med* 1989; 321:183-185.
163. Halperin JL, Fuster V. Left ventricular thrombus and stroke after myocardial infarction: Toward prevention or perplexity? *J Am Coll Cardiol* 1989; 14:912-914.
164. Stein B, Fuster V, Israel DH, Cohen M, Badimon L, Badimon JJ, Chesebro JH. Platelet inhibitor agents in cardiovascular disease: An update. *J Am Coll Cardiol* 1989; 14:813-836.
165. Cohen M, Fuster V, Steele PM, Driscoll D, McGoon DC. Coarctation of the aorta: Long-term follow-up and prediction of outcome after surgical correction. *Circulation* 1989; 80:840-845.
166. Machac J, Vallabhajosula S, Goldman ME, Goldsmith SJ, Palestro C, Strashun A, Vaquer R, Phillips R, Fuster V. Value of blood pool subtraction in cardiac indium-111 labeled platelet imaging. *J Nucl Med* 1989; 30:1445-1455.
167. Heras M, Chesebro JH, Webster M, Mruk J, Grill D, Badimon L, Fuster V. Prevention of thrombosis by recombinant hirudin during arterial angioplasty in pigs: Comparison with heparin. *J Am Coll Cardiol* 1989; 13:77A.
168. Stein B, Fuster V, Halperin J, Chesebro JH. Antithrombotic therapy in cardiac disease: An emerging approach based on the pathogenesis and risk. *Circulation* 1989; 80:1501-1513.
169. Stein B, Fuster V. Antithrombotic therapy in acute myocardial infarction: Prevention of venous, left ventricular and coronary artery thromboembolism. *Am J Cardiol* 1989; 64(Suppl B):33B-40B.
170. Badimon L, Badimon JJ, Turitto VT, Fuster V. Role of von Willebrand factor in mediating platelet-vessel wall interaction at low shear rate: The importance of perfusion conditions. *Blood* 1989; 73:961-967.
171. Badimon L, Badimon JJ, Galvez, Turitto V, Fuster V. Platelet interaction with vessel and collagen in pigs with homozygous von Willebrand's disease associated with abnormal collagen aggregation. *Thromb Haemost* 1989; 61:57-64.
172. Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, Doherty J, Read R, Chesler E, Sako Y, Lancaster L, Emery R, Sharma G, Josa M, Pacold I, Montoya A, Parikh D, Sethi G, Holt J, Kirklin J, Shabetai R, Moores W, Aldridge J, Masud Z, DeMots H, Floten S, Haakenson C, Harker LA (Fuster V, Data Monitoring Board). Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. *Circulation* 1989; 80:1190-1197.
173. Chesebro JH, Fuster V, Webster MWI. Endothelial injury and coronary vasomotion. *J Am Coll Cardiol* 1989; 14:1191-1192.
174. Gomes JG, Alexopoulos D, Winters SL, Deshmukh, Fuster V, Suh Kiung. The role of silent ischemia, the arrhythmic substrate and the short-long sequence in the genesis of sudden cardiac death. *J Am Coll Cardiol* 1989; 14:1618-1625.
175. Fuster V, Stein B, Badimon L, Badimon JJ, Ambrose JA, Chesebro JH. Atherosclerotic plaque rupture and thrombosis: Evolving concepts. *Circulation* 1990; 82(Suppl II):47-59.
176. Chesebro JH, Badimon L, Fuster V. New approaches to treatment of myocardial infarction. *Am J Cardiol* 1990; 65:12C-19C.
177. Fuster V, Stein B, Halperin JL, Chesebro JH. Antithrombotic therapy in cardiac disease: An approach based on pathogenesis and risk stratification. *Am J Cardiol* 1990; 65:38C-44C.
178. Stroke Prevention in Atrial Fibrillation Study Group Investigators: Preliminary report of the



- stroke prevention in atrial fibrillation study. *N Engl J Med* 1990; 322:862-868.
179. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. *J Clin Invest* 1990; 85:1234-1241.
  180. Stein B, Halperin JL, Fuster V. Prevention of left ventricular mural thrombosis and arterial embolism during and after acute myocardial infarction. *Coronary Artery Disease* 1990; 1:180-189.
  181. Cohen M, Fuster V. Unstable angina: Mechanisms and treatment. *Coronary Artery Disease* 1990; 1:166-169.
  182. Badimon JJ, Ip J, Badimon L, Fuster V. Thrombosis and accelerated atherosclerosis in coronary bypass surgery and restenosis after percutaneous transluminal coronary angioplasty: Implications for therapy. *Coronary Artery Disease* 1990; 1:170-179.
  183. Ip JH, Fuster V, Badimon L, Cohen M, Badimon JJ, Chesebro JH. Syndromes of accelerated atherosclerosis: Role of vascular injury and smooth muscle cell proliferation. *J Am Coll Cardiol* 1990; 15:1667-1687.
  184. Rogers WJ, Baim DS, Gore JM, et al for the TIMI II-A Investigators: Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the Thrombolysis in Myocardial Infarction (TIMI Phase II-A Trial). *Circulation* 1990; 81:1457-1476.
  185. Ryan TJ, Graham TP, Annas GJ, DeMaria AN, Fost NC, Fuster V, Harvey JC, Levinsky NG, McCullough LB, Rettig RA, Schwartz WJ, Sundwall DN, Talner NS, Wigle ED, Willman VL: Task Force III: Perspectives on the allocation of limited resources in cardiovascular medicine. *J Am Coll Cardiol* 1990; 16:17-23.
  186. Gunnar RM, Bourdillon PDV, Dixon DW, Fuster V, Karp RB, Kennedy JW, Klocke FJ, Passamani ER, Pitt B, Rapaport E, Reeves TJ, Russell RO, Sobel BE, Winters WL. ACC/AHA Task Force Report: Guidelines for early management of patients with acute myocardial infarction. *J Am Coll Cardiol* 1990; 16:249-292.
  187. Sanborn TA, Alexopoulos D, Marmur J, Kahn H, Badimon JJ, Badimon L, Fuster V. Coronary excimer laser angioplasty: Reduced complications, and indium-111 platelet accumulation compared to laser thermal angioplasty. *J Am Coll Cardiol* 1990; 16:502-506.
  188. Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Penyy WJ, Bowie EJW, Badimon L, Fuster V. Hirudin, heparin and placebo during deep arterial injury in the pig: The in vivo role of thrombin in platelet-mediated thrombosis. *Circulation* 1990; 82:1476-1484.
  189. Badimon JJ, Fuster V, Badimon L. Accelerated atherosclerosis and thrombosis in coronary bypass surgery and restenosis after PTCA: Implications for therapy. *Clin Invest Arteriosclerosis* 1990; 2:107-114.
  190. Chesebro JH, Fuster V, Halperin JL. Atrial fibrillation - Risk marker for stroke. *N Engl J Med* 1990; 323:1556.
  191. The Stroke Prevention in Atrial Fibrillation Investigators: Design of a multicenter randomized trial for the stroke prevention in atrial fibrillation study. *Stroke* 1990; 21:538-545.
  192. Cohen M, Fuster V. Insights into the pathogenetic mechanisms of unstable angina. *Haemostasis* 1990; 20(Suppl 1):102-112.
  193. Badimon L, Badimon JJ, Fuster V. Thrombogenesis and inhibition of platelet aggregation. Experimental aspects and future approaches. *Kardiologie* 1990; 79:133- 145.
  194. Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, Kern K, Sethi G, Sharma G, Khuri S, Richards K, Grover F, Morrison D, Johnston M, Chesler E, Sako Y, Pacold I, Montoya A, DeMots H, Floten S, Doherty J, Read R, Scott S, Spooner T, Masud Z, Haakenson C, Harker L (Fuster V, Data Monitoring Board). *Circulation* 1990; 82(suppl

- IV):IV-237-IV-242.
195. Cohen M, Adams PC, Hawkins L, Bach M, Fuster V. Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (A pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Group. *Am J Cardiol* 1990; 66:1287-1292.
  196. Fuster V, Ip JH, Badimon L, Badimon JJ, Stein B, Chesebro JH. Importance of experimental models for the development of clinical trials on thromboatherosclerosis. *Circulation* 1991; 83(Suppl IV):IV-15-IV-25.
  197. Ip JH, Fuster V, Israel D, Badimon L, Badimon J, Chesebro JH. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. *J Am Coll Cardiol* 1991; 17:77B-88B.
  198. Badimon L, Badimon JJ, Lassila R, Heras M, Chesebro JH, Fuster V. Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow condition in a porcine model. Effects of hirudins, heparin and calcium chelation. *Blood* 1991; 78:423-434.
  199. Marmur JD, Sanborn TA, Kahn H, Badimon JJ, Badimon L, Fuster V. Acute biological response to excimer versus thermal laser angioplasty in experimental atherosclerosis. *J Am Coll Cardiol* 1991; 17:978-984.
  200. Badimon JJ, Badimon L, Turitto VT, Fuster V. Platelet deposition at high shear rates is enhanced by high plasma cholesterol levels. Study in vivo in the rabbit model. *Arteriosclerosis & Thrombosis* 1991; 11:395-402.
  201. Chesebro JH, Fuster V. Dynamic thrombosis and thrombolysis: Role of antithrombins. *Circulation* 1991; 83:1815-1817.
  202. Cohen M, Hawkins L, Greenberg S, Fuster V. Usefulness of ST-segment changes in > 2 leads on the emergency room electrocardiogram in either unstable angina pectoris or non-Q-wave myocardial infarction in predicting outcome. *Am J Cardiol* 1991; 67:1368- 1373.
  203. Lam JYT, Chesebro JH, Steele PM, Heras M, Webster MWI, Badimon L, Fuster V. Antithrombotic therapy for deep arterial injury by angioplasty: Efficacy of common platelet inhibition compared with thrombin inhibition in pigs. *Circulation* 1991; 84:814-820.
  204. Fuster V, Badimon L, Badimon JJ, Ip JH, Chesebro JH. The porcine model for the understanding of thrombogenesis and atherogenesis. *Mayo Clin Proc* 1991; 66:818-831.
  205. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: Final results. *Circulation* 1991; 84:527-539.
  206. Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, Kern KB, Sethi G, Sharma GVRK, Khuri S, Richards K, Grover F, Morrison D, Whitman G, Chesler E, Sako Y, Pacold I, Montoya A, DeMots H, Floten S, Doherty J, Read R, Scott S, Spooner T, Masud Z, Haakenson C, Harker LA, and the Department of Veterans Affairs Cooperative Study Group (Fuster V, Data Monitoring Board). Starting aspirin therapy after operation: Effects on early graft patency. *Circulation* 1991; 84:520-526.
  207. Badimon L, Merino A, Badimon JJ, Fuster V. Trombosis arterial y activacion plaquetar. I. Fisiopatologia. *Rev Imberoamer Tromb Hemostasia* 1991; 4:73-80.
  208. Badimon L, Merino A, Badimon JJ, Fuster V. Trombosis arterial y activacion plaquetar. II. Tratamiento antitrombotico. *Rev Imberoamer Tromb Hemostasia* 1991; 4:81-88.
  209. Chesebro JH, Zoldhelyi P, Fuster V. Pathogenesis of thrombosis in unstable angina. *Am J Cardiol* 1991; 68:2B-10B.
  210. Chesebro JH, Badimon L, Fuster V. Importance of antithrombin therapy during coronary angioplasty. *J Am Coll Cardiol* 1991; 17:96B-100B.
  211. Chesebro JH, Zoldhelyi P, Fuster V. Plaque disruption and thrombosis in unstable angina

- pectoris. *Am J Cardiol* 1991; 68:9C-15C.
212. Habib GB, Heibig J, Forman SA, Brown BG, Roberts R, Terrin ML, Bolli R, and the TIMI Investigators. Influence of coronary collateral Vessels on myocardial infarct size in humans: Results of Phase I Thrombolysis in Myocardial Infarction (TIMI) Trial. (Fuster V, Safety and Data Monitoring Committee). *Circulation* 1991; 83:739-746.
  213. Israel DH, Fuster V, Ip JH, Chesebro JH. Antithrombotic therapy in acute myocardial infarction. *Thromb Haemorrh Disorders* 1991; 4:33-41.
  214. Baim DS, Diver DJ, Feit F, Greenberg MA, Holmes DR, Weiner BH, Williams DO, Schweiger MJ, Brown BG, Frederick MM, Knatterud GL, Braunwald E, for the TIMI II Investigators. (Fuster V, Safety and Data Monitoring Committee). Coronary angioplasty performed within the thrombolysis in myocardial infarction II study. *Circulation* 1992; 85:93- 105.215.
  215. Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Fuster V. Antithrombotic efficacy of low-molecular-weight heparin in deep arterial injury. *Arteriosclerosis and Thrombosis* 1992; 12:250-255.
  216. Ferrell M, Fuster V, Gold HK, Chesebro JH. A dilemma for the 1990's: Choosing the appropriate experimental animal model for the prevention of restenosis. *Circulation* 1992;85:1630-31.
  217. Betriu A, Heras M, Cohen M, Fuster V. Unstable angina: Outcome according to clinical presentation. *J Am Coll Cardiol* 1992; 19:1659-63.
  218. Fuster V, Badimon L, Badimon JJ, Chesebro JH. Coronary artery disease: Progression and acute coronary syndromes (Part 1). *N Engl J Med* 1992; 326:242-250.
  219. Fuster V, Badimon L, Badimon JJ, Chesebro JH. Coronary artery disease: Progression and acute coronary syndromes (Part 2). *N Engl J Med* 1992; 326:310-318.
  220. Kleiman NS, Terrin M, Mueller H, Chaitman B, Roberts R, Knatterud GL, Solomon R, McMahon RP, Braunwald E, and the TIMI Investigators. Mechanisms of early death despite thrombolytic therapy: Experience from the thrombolysis in myocardial infarction phase II (TIMI II) study. *JAm Coll Cardiol* 1992;19:1129-35.
  221. Mueller HS, Cohen LS, Braunwald E, Forman S, Feit F, Ross A, Schweiger M, Cabin H, Davison R, Miller D, Solomon R, Knatterud GL, for the TIMI Investigators. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the thrombolysis in myocardial infarction (TIMI) trial, phase II. *Circulation* 1992;85:1254-64.
  222. Williams DO, Braunwald E, Knatterud , Babb J, Bresnahan J, Greenberg MA, Raizner A, Wasserman A, Robertson T, Ross R, and TIMI Investigators. One-year results of the thrombolysis in myocardial infarction investigation (TIMI) phase II trial. *Circulation*1992;85:533-42.
  223. Lam JYT, Badimon JJ, Ellefson RD, Fuster V, Chesebro JH. Cod liver oil alters platelet-arterial wall response to injury in pigs. *Circ Res* 1992; 71:769-775
  224. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillations: I. Clinical features of patients at risk. *Ann Intern Med* 1992;116:1-5.
  225. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillations: II: Echocardiographic features of patients at risk. *Ann Intern Med* 1992;116:6-12.
  226. The Stroke Prevention in Atrial Fibrillation Investigators. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. *J Am Coll Cardiol* 1992; 20:527-32.
  227. Fuster V (Guest Editor). Progression-Regression of Atherogenesis: Molecular, Cellular, and Clinical Bases (Supplement to *Circulation*). *Circulation* 1992; 86(Suppl III).

228. Fuster V, Badimon JJ, Badimon L. Clinical-pathological correlations of coronary disease progression and regression. *Circulation* 1992; 86(Suppl III):III-1-III-11.
229. Badimon JJ, Fuster V, Badimon L. Role of high density lipoproteins in the regression of atherosclerosis. *Circulation* 1992; 86(Suppl III):III-86-III-94.
230. Badimon L, Badimon JJ, Gold HK, Fuster V. Coronary atherosclerosis: Morphology and characteristics to identify by evolving imaging technology. *Am J Cardiac Imag* 1992; 6:278-288.
231. Cairns JA, Fuster V, Kennedy JW. Coronary thrombolysis. *Chest* 1992; 102:482S-507S.
232. Hirsh J, Dalen JE, Fuster V, Harker LB, Salzman EW. Aspirin and other platelet-active drugs: The relationship between dose, effectiveness, and side effects. *Chest* 1992; 102:237S-336S.
233. Merino A, Hauptman P, Badimon L, Badimon JJ, Cohen M, Fuster V, Goldman M. Echocardiographic "smoke" is produced by an interaction of erythrocytes and plasma proteins modulated by shear forces. *J Am Coll Cardiol* 1992; 20:1661-1668.
234. Zoldhelyi P, Fuster V, Chesebro JH. Antithrombins as conjunctive therapy in arterial thrombolysis. *Coronary Artery Disease* 1992; 3:1003-1009.
235. Jang I-K, Fuster V, Gold HK. Antiplatelets. *Coronary Artery Disease* 1992; 3:1030-1036.
236. Sugrue DD, Rodeheffer RJ, Codd MB, Ballard DJ, Fuster V, Gersh BJ. The clinical course of idiopathic dilated cardiomyopathy: A population-based study. *Ann Intern Med* 1992; 117:117-23.
237. Chesebro JH, Fuster V. Thrombosis in unstable angina. *N Engl J Med* 1992;327:192-194.
238. Lam JYT, Chesebro JH, Badimon L, Fuster V. Exogenous prostacyclin decreases vasoconstriction but not platelet thrombus deposition after arterial injury. *J Am Coll Cardiol* 1993; 21:488-492.
239. Ridker PM, Hebert PR, Fuster V, Hennekens CH. Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction? *The Lancet* 1993; 341:1574-1577.
240. Badimon L, Badimon JJ, Chesebro JH, Fuster V. Von Willebrand Factor and Cardiovascular Disease. *Thrombosis and Haemostasis* 1993; 70:111-118.
241. Marmur JD, Taubman MB, Fuster V. Pathophysiology of restenosis: The role of platelets and thrombin. *J Vasc Med Biol* 1993; 4:55-63.
242. Fuster V. Coronary thrombolysis - A perspective for the practicing physician. *N Engl J Med* 1993; 329:723-5.
243. Murphy JG, Gersh BJ, Mair DD, Fuster V, McGoon MD, Ilstrup DM, McGoon DC, Kirklin JW, Danielson GK. Long-term outcome in patients undergoing surgical repair of Tetralogy of Fallot. *New Engl J Med* 1993;329:593-9.
244. Zoldhelyi P, Webster MWI, Fuster V, Grill DE, Gaspar D, Edwards SJ, Cabot CF, Chesebro JH. Recombinant hirudin in patients with chronic, stable coronary artery disease: safety, half-life, and effect on coagulation parameters. *Circulation* 1993; 88[part 1]:2015-2022.
245. Higenbottam TW, Spiegelhalter D, Scott JP, Fuster V, Dinh-Xuan AT, Caine N, Wallwork J. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. *Br Heart J* 1993; 70:366.
246. Cohen M, Xiong J, Parry G, Adams PC, Chamberlain D, Wieczorek I, Fox KAA, McBride R, Chesebro JH, Fuster V. Prospective comparison of unstable angina versus non-Q wave myocardial infarction during antithrombotic therapy. *J Am Coll Cardiol* 1993; 22:1338-1343.
247. Fuster V, Dyken ML, Vokonas PS, Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. *Circulation* 1993; 87:659-675.

248. Lerman A, Webster MWI, Chesebro JH, Edwards WD, Wei C-M, Fuster V, Burnett JC. Circulating and tissue endothelin immunoreactivity in hypercholesterolemic pigs. *Circulation* 1993; 88:2923-2928.
249. Badimon JJ, Fuster V, Chesebro JH, Badimon L. Coronary Atherosclerosis: A multifactorial disease. *Circulation* 1993; 87(Suppl II):II-3 - II-16.
250. Jang I-K, Lassila R, Fuster V. Atherogenesis and inflammation. *Eur Heart J* 1993; 14(Suppl K):2-6.
251. The RAPT Investigators (Fuster V, Data and Safety Monitoring Committee). Ridogrel, a combined thromboxane A2 synthase inhibitor and prostaglandin/endoperoxide receptor antagonist, vs aspirin as conjunctive therapy for thrombolysis. The Ridogrel vs Aspirin Patency Trial (RAPT). *Circulation* 1994; 89:588-595.
252. Alexopoulos D, Sanborn TA, Marmur JD, Badimon JJ, Badimon L, Dische R, Fuster V. The acute biological response to laser balloon angioplasty in the atherosclerotic rabbit. *Lasers in Surgery and Medicine* 1994; 14:7-12.
253. Fuster V. In memory of Dr. Simon Dack. *J Am Coll Cardiol* 1994; 23:1265.
254. Antiplatelet Trialists' Collaboration (Fuster V, Collaborator). Collaborative overview of randomized trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. *Br Med J* 1994; 308:81-106.
255. Antiplatelet Trialists' Collaboration (Fuster V, Collaborator). Collaborative overview of randomized trials of antiplatelet therapy II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. *Br Med J* 1994; 308:159-168.
256. Antiplatelet Trialists' Collaboration (Fuster V, Collaborator). Collaborative overview of randomized trials of antiplatelet therapy III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. *Br Med J* 1994; 308:235-246.
257. Israel DH, Sharma SK, Fuster V. Antithrombotic therapy in prosthetic heart valve replacement. *Am Heart J* 1994; 127:400-411.
258. Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wiczorek I, Fox KAA, Chesebro JH, Strain J, Keller C, Kelly A, Lancaster G, Ali J, Kronmal R, Fuster V. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: Primary end points analysis from the ATACS trial. *Circulation* 1994; 89:81-88.
259. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: Heparin. *Circulation* 1994; 89:1449-1468.
260. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 2: Oral Anticoagulants. *Circulation* 1994; 89:1469-1480.
261. Badimon JJ, Weng D, Chesebro JH, Fuster V, Badimon L. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity. *Thrombosis and Haemostasis* 1994; 71:1-7.
262. Fernandez-Ortiz A, Meyer BJ, Mailhac A, Falk E, Badimon L, Fallon JT, Fuster V, Chesebro JH, Badimon JJ. A new approach for local intravascular drug delivery: Iontophoretic balloon. *Circulation* 1994; 89:1518-1522.
263. Topol EJ, Fuster V, Harrington RA, Califf RM, Kleinman NS, Kereiakes DJ, Cohen M, Chapekis A, Gold HK, Tannenbaum MA, Rao AK, Debowey D, Schwartz D, Henis M, Chesebro J. Recombinant hirudin for unstable angina pectoris: A multicenter, randomized angiographic trial. *Circulation* 1994; 89:1557-1566.
264. Fernandez-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, Weng D, Shah PK, Badimon L. Characterization of the relative thrombogenicity of atherosclerotic plaque

- components: Implications for consequences of plaque rupture. *J Am Coll Cardiol* 1994; 23:1562-1569.
265. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes: Implications for plaque rupture. *Circulation* 1994; 90:775-778
266. Schechter AD, Chesebro JH, Fuster V. Refractory Prinzmetal angina treated with cyproheptadine. *Ann Intern Med* 1994; 121:113-114.
267. Fuster V, Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction insights from studies of vascular biology. *Circulation* 1994; 90:2126-2146.
268. Huggins G, Fuster V. Left ventricular thromboembolism after myocardial infarction. *Heart Disease and Stroke* 1994; 3:355-360.
269. Meyer BJ, Badimon JJ, Mailhac A, Fernandez-Ortiz A, Chesebro JH, Fuster V, Badimon L. Inhibition of growth of thrombus on fresh mural thrombus: Targeting optimal therapy. *Circulation* 1994; 90:2432-2438.
270. Meyer B, Fernandez-Ortiz A, Mailhac A, Falk E, Badimon L, Michael AD, Chesebro JH, Fuster V, Badimon JJ. Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty. *Circulation* 1994; 90:2474-2480.
271. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. *N Engl J Med* 1994; 331:1564-1575.
272. Goodman SG, Langer A, Durica SS, Raskob GE, Comp PC, Gray RJ, Hall JH, Kelley P, Hua TA, Lee RJ, Fuster V, for the Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. *Am J Cardiol* 1994; 74:657-661.
273. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. *Circulation* 1994; 90:1631-1637.
274. Alexopoulos D, Sanborn TA, Marmur JD, Badimon JJ, Badimon L, Dische R, Fuster V. Acute biological response to laser balloon angioplasty in the atherosclerotic rabbit. *Lasers in Surgery and Medicine* 1994; 14:7-12.
275. Fuster V, Halperin JL. Aortic Dissection: A medical perspective. *J Card Surg* 1994; 9:713-728.
276. King SB, Frye RL, Fuster V, Garson A, Gay WA Jr., Popp RL. 25<sup>th</sup> Bethesda Conference: Future Personnel Needs for Cardiovascular Health Care Task Force 2: Academic Health Centers. *J Am Coll Cardiol* 1994; 24:275-328.
277. Falk E, Fallon JT, Mailhac A, Fernandez-Ortiz A, Meyer B, Weng D, Shah PK, Badimon JJ, Fuster V. Muramidase: A useful monocyte/macrophage immunocytochemical marker in swine of special interest in experimental cardiovascular disease. *Cardiovascular Pathology* 1994; 3:183-189.
278. Cohen M, Parry G, Adams PC, Xiong J, Chamberlain D, Wieczorek I, Fox KAA, Kronmal R, Fuster V, and the Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Prospective evaluation of a prostacyclin-sparing aspirin formulation and heparin/warfarin in aspirin users with unstable angina or non-Q wave myocardial infarction at rest. *Eur Heart J* 1994; 15:1196-1203.
279. Merino A, Cohen M, Badimon JJ, Fuster V, Badimon L. Synergistic action of severe wall injury and shear forces on thrombus formation in arterial stenosis: Definition of a thrombotic shear rate threshold. *J Am Coll Cardiol* 1994; 24:1091-1094.
280. Zoldehlyi P, Bichler J, Owen WG, Grill DE, Fuster V, Mruk JS, Chesebro JH. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin.

- Circulation* 1994; 90:2671-2678.
281. Pearson T, Rapaport E, Criqui M, Furgberg C, Fuster V, Hiratzka L, Little W, Ockene I, Williams G. Optimal risk factor management in the patient after coronary revascularization: A statement for healthcare professionals from an American Heart Association Writing Group. *Circulation* 1994; 90:3125-3133.
  282. Toussaint J-F, Southern JF, Fuster V, Kantor HL. <sup>13</sup>C-NMR spectroscopy of human atherosclerotic lesions: Relation between fatty acid saturation, cholesteryl ester content, and luminal obstruction. *Arterioscler. Thromb.* 1994; 14:1951-1957.
  283. Mailhac A, Badimon JJ, Fallon JT, Fernandez-Ortiz A, Meyer B, Chesebro JH, Fuster V, Badimon L. Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis. Relative contribution of fibrin(ogen) and platelet. *Circulation* 1994; 90:988-996.
  284. Braunwald E, Jones RH, Mark DB, Brown J, Brown L, Cheitlin MD, Concannon CA, Cowan M, Edwards C, Fuster V, Goldman L, Green LA, Grines CL, Lytle BW, McCauley KM, Mushlin AI, Rose GC, Smith EE, Swain JA, Topol EJ, Willerson JT. Diagnosing and managing unstable angina. *Circulation* 1994; 90:613-622.
  285. Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR, Danielson GK, Orszulak TA, Pluth JR, Puga FJ, Schaff HV, Larsonkeller JJ. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. *J Am Coll Cardiol* 1995; 25:1111-1119.
  286. Smith SC, Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ, Gotto AM, Gould KL, Greenland P, Grundy SM, Hill MN, Hlatky MA, Houston-Miller N, Krauss RM, LaRosa J, Ockene IS, Oparil S, Pearson TA, Rapaport E, Starke RD. Consensus Panel Statement: Preventing heart attack and death in patients with coronary disease. *Circulation* 1995; 92:2-4.
  287. Badimon L, Chesebro JH, Badimon JJ, Fuster V. Arterial angioplasty: Thrombosis and restenosis. *J Physiol Pharmacol* 1996(In press).
  288. Fuster V, Badimon JJ. Regression or stabilization of atherosclerosis means regression or stabilization of what we don't see in the arteriogram. *Eur Heart J* 1995; 16:6-12.
  289. Fuster V, Chesebro JH. Aspirin for primary prevention of coronary disease: An aspirin a day? *Eur Heart J* 1995; 16:16-20.
  290. Fuster V. Elucidation of the role of plaque instability and rupture in acute coronary events. *Am J Cardiol* 1995; 76:24C-33C.
  291. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Circulation* 1995; 92:1355-1374.
  292. Falk E, Shah PK, Fuster V. Coronary plaque disruption. *Circulation* 1995; 92:657-671.
  293. Falk E, Fuster V. Angina pectoris and disease progression. *Circulation* 1995; 92:2033-2035.
  294. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Arterioscler Thromb Vasc Biol* 1995; 15:1512-1531.
  295. Chesebro JH, Badimon JJ, Hassinger NL, McBane RD, Fuster V. Acute myocardial infarction and the role of aspirin, heparin, and warfarin. *Journal of Thrombosis and Thrombolysis* 1995; 1:231:235.

296. Toussaint J-F, Southern JF, Fuster V, Kantor HL. T2-weighted contrast for NMR characterization of human atherosclerosis. *Arterioscler Thromb Vasc Biol* 1995; 15:1533-1542.
297. Fernandez-Ortiz A, Meyer B, Chesebro JH, Fuster V, Badimon JJ. Potential applications of iontophoresis for local drug delivery of vascular diseases. *J Interven Cardiol* 1995; 8:420.
298. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, Fallon JT, Regnstrom J, Fuster V. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. *Circulation* 1995; 92:1565.
299. Vorchheimer DA, Fuster V. Coumadin Aspirin Reinfarction Study: Rationale and Design of the CARS Study. *J Thrombos & Thrombolysis* 1995; 2:171-176.
300. Cairns JA, Fuster V, Gore J, Kennedy JW. Coronary thrombolysis. *Chest* 1995; 108 (Suppl Oct):401S-423S.
301. Hirsh J, Dalen JE, Fuster V, Harker L, Patrono C, Roth GJ. Aspirin and other platelet-active drugs: The relationship between dose, effectiveness, and side effects. *Chest* 1995; 108(Suppl Oct):247S.
302. Fuster V, Falk E, Fallon JT, Badimon L, Chesebro JH, Badimon JJ. The three processes leading to post PTCA restenosis: Dependence on the lesion substrate. *Thrombosis and Haemostasis* 1995; 74:552-559.
303. Badimon L, Alfon J, Royo T, Berrozpe M, Martinez-Gonzalez J, Vidal F, Chesebro JH, Fuster V, Badimon JJ. Cell biology of restenosis post-angioplasty. *Z Kardiol* 1995; 84(Suppl 4):145-149.
304. Goldman ME, Fisher EA, Winters S, Reichstein R, Stavile K, Gorlin R, Fuster V. Early identification of patients with native valve infectious endocarditis at risk for major complications by initial clinical presentation and baseline echocardiography. *International Journal of Cardiology* 1995; 52:257-264.
305. Langer A, Fisher M, Califf RM, Goodman S, O'Connor CM, Harrington RA, Fuster V. for the CARS Investigators. Higher rates of Coronary angiography and revascularization following myocardial infarction may be associated with greater survival in the United States than in Canada. *Can J Cardiol* 1999;15:1095-1102.
306. Mruk JS, Zoldhelyi P, Webster MWI, Heras M, Grill DE, Holmes DR, Fuster V, Chesebro JH. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of r-hirudin, heparin or aspirin. *Circulation* 1996; 93:792-799.
307. Toussaint JF, LaMuraglia GM, Southern JF, Fuster V, Kantor HL. Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo. *Circulation* 1996; 94:932-938.
308. Prystowsky EN, Benson DW, Fuster V, Hart RG, Kay GN, Myerburg RJ, Naccarelli GV, Wyse G. Special report: Management of patients with atrial fibrillation: A report for health professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. *Circulation* 1996; 93:1262-1277.
309. Fuster V, Pearson TA (Co-Chairs). 27<sup>th</sup> Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary disease events. *J Am Coll Cardiol* 1996;27:957-1047.
310. Fuster V, Gotto AM, Libby P, Loscalzo J, McGill H. Task Force 1. Pathogenesis of coronary disease: The biologic role of risk factors. *J Am Coll Cardiol* 1996; 7(5):964-975.
311. Pearson TA, Fuster V. Executive Summary. 27<sup>th</sup> Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary disease events. *J Am Coll Cardiol* 1996;27(5):961-963.



312. Smith AJC, Holt RE, Fitzpatrick K, Palacios IF, Gold HK, Werner W, Bovill EG, Fuster V, Jank IK. Transient thrombotic state after abrupt discontinuation of heparin in percutaneous coronary angioplasty. *Am Heart J* 1996;131:434-439.
313. Dangas G, Fuster V. Management of restenosis after coronary intervention. *Am Heart J* 1996; 132(2):428-436.
314. Wexler L, Brundage B, Crouse J, Detrano R, Fuster V, Maddahi J, Rumberger J, Stanford W, White R, Taubert K. Coronary artery calcification: Pathophysiology, epidemiology, imaging methods and clinical implications. *Circulation* 1996;94:1175-1192.
315. Rao AK, Sun L, Chesebro JH, Fuster V, Harrington RA, Schwartz D, Gallo P, Matos D, Topol EJ. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial. *Circulation* 1996; 94:2389-2395.
316. Moreno PR, Bernardi VH, Lopez-Cuellar J, Murcia AM, Palacios IF, Gold HK, Mehran R, Sharma SK, Nemerson Y, Fuster V, Fallon JT. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. *Circulation* 1996;94:3090-3097.
317. Moreno PR, Bernardi VH, Lopez-Cuellar J, Newell JB, McMellon C, Gold HK, Palacios IF, Fuster V, Fallon JT. Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina. *Circulation* 1996; 94:3098-3102.
318. Chesebro JH, Fuster V. Optimal antithrombotic therapy for mechanical prosthetic heart valves. *Circulation* 1996;94:2055-2056.
319. Cohen M, Adams PC, McBride R, Fuster V. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Prospective comparison of patient characteristics and outcome of non-prior aspirin users versus aspirin users with unstable angina or non-Q-wave myocardial infarction treated with combination antithrombotic therapy. *J Thrombosis and Thrombolysis* 1997;4:275-280.
320. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. *Circulation* 1997;95:594-599.
321. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) I b Investigators (Fuster V, Investigator). A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. *N Engl J Med* 1996;335:775-782.
322. Fuster V, Fallon JT, Nemerson Y. Coronary thrombosis. *Lancet* 1996;348 (Suppl I):s7-s10.
323. Caprie Steering Committee (Fuster V, Study Chairman). A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). *Lancet* 1996; 348:1329-1339.
324. Fuster V, Vorchheimer DA. Prevention of atherosclerosis in coronary artery bypass grafts. *N Engl J Med* 1997;336(3):212-213.
325. Ambrose JA, Fuster V. Editorial. Can we predict future acute coronary events in patients with stable coronary artery disease? *JAMA* 1997;277:343-344.
326. Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. *N Engl J Med* 1997;336:267-276.
327. The Post Coronary Artery Bypass Graft Trial Investigators (Fuster V, Investigator). The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary artery bypass grafts. *N Engl J M* 1997;336:153-162.
328. Nash IS, Nash DB, Fuster V. Do cardiologists do it better? *J Am Coll Cardiol* 1997;29:475-478.

329. Chilian WM, NHLI Workshop Participants (Fuster V, Participant). Coronary microcirculation in health and disease. *Circulation* 1997;95:522-528.
330. Toussaint JF, Southern JF, Fuster V, Kantor HL. Water diffusion properties of human atherosclerosis and thrombosis measured by pulse field gradient nuclear magnetic resonance. *Arterioscler Thromb Vasc Biol* 1997;17:542-546.
331. Fuster V, Fallon JT, Badimon JJ, Nemerson Y. The unstable atherosclerotic plaque: Clinical significance and therapeutic intervention. *Thrombosis and Haemostasis* 1997;78(1):247-255.
332. Lengyel M, Fuster V, Keltai M, Roudaut R, Schulte HD, Seward JB, Chesebro JH, Turpie AGG. Guidelines for the management of left-sided prosthetic valve thrombosis. A role for thrombolytic therapy. *J Am Coll Cardiol* 1997;30:1521-1526.
333. Fuster V, Nash I. The generalist/cardiovascular specialist: A proposal for a new training track. *Ann Intern Med* 1997;127:630-634.
334. Mehta D, Curwin J, Gomes JA, Fuster V. Sudden death in coronary disease: Acute ischemia versus myocardial substrate. *Circulation* 1997;96:3215-3223.
335. The Mechanisms Precipitating Acute Cardiac Events Group (Fuster V, member). Mechanisms precipitating acute cardiac events: Review and recommendations of an NHLBI Workshop. *Circulation* 1997;96:3233-3239.
336. Badimon JJ, Meyer B, Feigen LP, Baron DA, Chesebro JH, Fuster V, Badimon L. Thrombosis triggered by severe arterial lesions is inhibited by oral administration of a glycoprotein I b/IIIa antagonist. *Eur J Clin Inv* 1997;27:568-574.
337. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease. A statement for healthcare professionals from the American Heart Association Writing Group. *Circulation* 1997;96:2751-2753.
338. Schussheim A, Fuster V. Thrombosis, antithrombotic agents, and the antithrombotic approach in cardiac disease. *Progress in Cardiovascular Disease* 1997;40(3):205-238.
339. Vallabhajosula S, Fuster V. Atherosclerosis: Imaging techniques and the evolving role of nuclear medicine. *J Nucl Med* 1997;38:1788-1796.
340. Fuster V. Principal Investigator: Coumadin Aspirin Reinfarction Study (CARS). Randomized Double Blind trial of fixed low dose warfarin with aspirin after acute myocardial infarction. *Lancet* 1997;350:389.
341. Harnick DJ, Cohen JL, Schechter CB, Fuster V, Smith DA. Effects of practice setting on quality of lipid lowering management in patients with coronary artery disease. *Am J Cardiol* 1998;81(12):1416-20.
342. Gutstein DE, Fuster V. Pathophysiologic bases for adjunctive therapies in the treatment and secondary prevention of acute myocardial infarction. *Clin Cardiol* 1998;21:161-168.
343. Ambrose JA, Fuster V. Editorial. The risk of coronary occlusion is not proportional to the prior severity of coronary stenosis. *Heart* 1998;79:3-4.
344. Adams PC, Skinner JS, Cohen M, McBride R, Fuster V, The Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Acute coronary syndromes in the United States and United Kingdom: A comparison of approaches. *Clin Cardiol* 1998;21:348-352.
345. Toussaint J-F, Southern JF, Kantor HL, Jang I-K, Fuster V. Behavior of atherosclerotic plaque components after in vitro angioplasty and atherectomy studied by high field MR imaging. *Magnetic Resonance Imaging* 1998;16(2):175-183.
346. Metz BK, White HD, Granger CB, Simes RJ, Armstrong PW, Hirsh J, Fuster V, MacAulay CM, Califf RM, Topol EJ for the GUSTO IIb Investigators. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: Results from the GUSTO IIb Trial. *J Am Coll Cardiol* 1998;31:1493-1498.

347. Vorchheimer DA, Fuster V. Oral platelet glycoprotein I b/IIIa antagonists: The present challenge is safety. *Circulation* 1998;97:312-314.
348. Gallo R, Padurean A, Toschi V, Bichler J, Fallon JT, Chesebro JH, Fuster V, Badimon JJ. Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries. *Circulation* 1998;97:581-588.
349. Meyer BJ, Badimon JJ, Chesebro JH, Fallon JT, Fuster V, Badimon L. Dissolution of mural thrombus by specific thrombin inhibition with r-Hirudin. Comparison with heparin and aspirin. *Circulation* 1998;97:681-685.
350. Fuster V. Mechanisms of arterial thrombosis: Foundation for therapy. *Am Heart J* 1998;135:S361-S366.
351. Fayad Z, Fallon JT, Shinnar M, Dansky HM, Poon M, Badimon JJ, Charlton SA, Fisher EA, Breslow JL, Fuster V. Noninvasive in vivo high resolution magnetic resonance imaging of atherosclerotic lesions in genetically-engineered mice. *Circulation* 1998;98: 1541-1547.
352. Gertz DS, Fallon JT, Gallo R, Taubman MB, Banai S, Barry WL, Gimple LW, Nemerson Y, Thiruvikraman S, Naidu SS, Chesebro, JH, Fuster V, Sarembock IJ, Badimon JJ. Hirudin reduces tissue factor expression in Neointima after balloon injury in rabbit femoral and porcine coronary arteries. *Circulation* 1998;98: 580-587.
353. Badimon JJ, Fernandez-Ortiz A, Meyer B, Mailhac A, Fallon JT, Falk E, Badimon L, Chesebro JH, Fuster V. Different response to balloon angioplasty of carotid and coronary arteries: effects on acute platelet deposition and intimal thickening. *Atherosclerosis* 1998;140:307-314.
354. Cairns JA, Kennedy JW, Fuster V. Coronary Thrombolysis. *Chest* 1998;634S-657S.
355. Fuster V, Fayad ZA, Badimon JJ. Acute Coronary Syndromes: Biology. *Lancet* 1999;353:SII5-SII9.
356. Gallo R, Padurean A, Jayamaran T, Marx S, Roque M, Adelman S, Chesebro J, Fallon J, Fuster V, Marks, A, Badimon JJ. Inhibition of Intimal Thickening after Balloon Angioplasty in Porcine Coronary Arteries by Targeting Regulators of the Cell Cycle. *Circulation* 1999;99:2164-2170.
359. Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, Badimon L. Local Inhibition of Tissue Factor Reduces the Thrombogenicity of Disrupted Human Atherosclerotic Under Flow Conditions. *Circulation* 1999;99:1780-1787.
360. Vorchheimer DA, Badimon JJ, Fuster V. Platelet Glycoprotein I Ib/IIIa Receptor Antagonists in Cardiovascular Disease. *JAMA* 1999;281:1407-1414.
361. Moreno PR, Palacios IF, Leon MN, Rhodes J, Fuster V, Fallon JT. Histopathologic Comparison of Human Coronary In-stent and Post-Balloon Angioplasty Restenotic Tissue. *Amer J Cardiol* 1999;84:462-465.
362. Grundy SM, Pasternack R, Greenland P, Smith S, Fuster V. Assessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations: a statement for healthcare professionals from the American heart association and the American college of cardiology. *Circulation* 1999;100:1481-1492.
363. Langer A, Fisher M, Claiff RM, Goodman S, O'Connor CM, Harrington RA, Fuster V. Higher Rates of Coronary Angiography and Revascularization following Myocardial Infarction may be associated with greater survival in the United States than in Canada. *Can J Cardiol* 1999;15:1095-1102.
364. Moreno PR, Fallon JT, Bernardi VH, Harrell L, Weissman NJ, Fuster V, Rodriguez A, Palacios IF. Histopathology of Coronary Lesions with early loss of minimal luminal diameter after

- successful percutaneous transluminal coronary angioplasty: Is thrombus a significant contributor? *Amer Heart J* 1999;136:804-811.
365. Reis ED, Roque M, Cordon-Cardo C, Fuster V, Badimon JJ. Time Course of p27 Expression after Femoral Arterial Injury in the Mouse. *Vascular Surgery* 1999;L:482-483.
366. Freudenberger R, Alexis J, Gass A, Fuster V, Badimon JJ. Antithrombotic Effect of FK506 vs Cyclosporine in Cardiac Transplant Recipients: Potential Implications in Transplant Arteriopathy. *Journal of Heart and Lung Transplant* 1999;18:1228-1231.
367. Moreno PR, Fallon JT, Murcia AM, Leon MN, Simosa H, Fuster V, Palacios IF. Tissue Characteristics of Restenosis after Percutaneous Transluminal Coronary Angioplasty in Diabetic Patients. *JACC* 1999;34:1045-1049.
368. Shinnar M, Fallon JT, Wehrli S, Levin M, Dalmacy D, Fayad ZA, Badimon JJ, Harrington M, Harrington E, Fuster V. The diagnostic accuracy of ex vivo MRI for human atherosclerotic plaque characterization. *Arterioscler Thromb Vasc Biol.* 1999 Nov;19(11):2756-61.
369. Grundy SM, Pasternak R, Greenland P, Smith S, Fuster V. AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. *Circulation.* 1999;100:(14)81-92 and *J Am Coll Cardiol.* 1999.Oct;34(4):1348-59.
370. Fuster V, Smaha L. AHA's new strategic impact goal designed to curb epidemic of cardiovascular disease and stroke. *Circulation.* 1999 May 11;99(18):2360.
371. Fuster V. Epidemic of cardiovascular disease and stroke: the three main challenges. *Circulation.* 1999 Mar 9;99(9):1132-7.
372. Roque M, Rauch U, Reis ED, Chesebro JH, Fuster V, Badimon JJ. Comparative study of antithrombotic effect of a low molecular weight heparin and unfractionated heparin in an ex vivomodel of deep arterial injury. *Thromb Res.* 2000 Jun 15;98(6):499-505.
373. Rauch U, Crandall J, Osende JI, Fallon JT, Chesebro JH, Fuster V. Increased thrombus formation relates to ambient blood glucose and leukocyte count in diabetes mellitus type 2. *Am J Cardiol.* 2000 Jul 15;86(2):246-9.
374. Fuster V. [Thrombus remodeling. Key factor in the progression of coronary atherosclerosis]. *Rev Esp Cardiol.* 2000;53 Suppl 1:2-7.
375. Helft G, Osende JI, Worthley SG, Zaman AG, Rodriguez OJ, Lev EI, Farkouh ME, Fuster V, Badimon JJ, Chesebro JH. Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin. *Arterioscler Thromb Vasc Biol.* 2000 Oct;20(10):2316-21.
376. Reis, ED, Roque M, Cordon-Cardo C, Drobnjak M, Fuster V, Badimon JJ. Apoptosis, proliferation, and p27 expression during vessel wall healing: time course study in a mouse model of transluminal femoral artery injury. *J Vasc Surg.* 2000 Nov;32(5):1022-9.
377. Fuster V, Gotto AM. Risk Reduction. *Circulation.* 2000 Nov 14;102(20 Suppl 4):IV94-IV102.
378. Worthley SG, Helft G, Fuster V, Zaman AG, Fayad ZA, Fallon JT, Badimon JJ. Serial In vivo MRI documents arterial remodeling in experimental atherosclerosis. *Circ.* 2000;101:586-589.
379. Greenland P, Abrams J, Aurigemma GP, Bond MG, Clark LT, Criqui MH, Crouse JR, Friedman L, Fuster V, Herrington DM, Kuller LH, Ridker PM, Roberts WC, Stanford W, Stone N, Swan, HJ, Taubert KA, Wexler L. Prevention Conference V. Beyond Secondary Prevention: Identifying the high-risk patient for primary prevention: Non invasive tests of

- atherosclerotic burden. *Circ* 2000;101:e16-e22.
380. Fayad ZA and Fuster V. Characterization of atherosclerotic plaques by magnetic resonance imaging. *Annals New York Academy of Sciences*. 2000 Characterization of atherosclerotic plaques by magnetic resonance imaging. *Ann N Y Acad Sci*. 2000 May;902:173-86.
  381. Worthley SG, Heft G, Fuster V, Fayad ZA, Fallon JT, Osende JI, Roque M, Shinnar M, Zaman AG, Rodriguez OJ, Verhallen P, Badimon JJ. High resolution ex vivo magnetic resonance imaging of in situ coronary and aortic atherosclerotic plaque in a porcine model. *Atherosclerosis*. 2000;150:321-9.
  382. Fayad ZA, Nahar T, Fallon JT, Goldman M, Aguinaldo JG, Badimon JJ, Shinnar M, Chesebro JH, Fuster V. In Vivo MR Evaluation of Atherosclerotic Plaques in the Human Thoracic Aorta: A Comparison with TEE. *Circ*. 2000 101: 2503-2509.
  383. Fayad ZA. Fuster V, Fallon JT, Jayasundera T, Worthley SG, Helft GMD; Aguinaldo JG, Badimon JJ, Sharma Noninvasive in vivo human coronary artery lumen and wall imaging using black blood magnetic resonance. *Circ*. 2000;102:506-10.
  384. Worthley SG, Helft G, Fayad ZA, Fuster V, Zaman AG, Shinnar M, Badimon JJ. Magnetic resonance imaging and asymptomatic aortic dissection. *Circ*. 2000;101:2771.
  385. Worthley SG, Helft G, Fayad ZA, Fuster V, Rodriguez OJ, Zaman AG, Fallon JT, JJ Badimon. Noninvasive in vivo magnetic resonance imaging of experimental coronary artery lesions in a porcine model. *Circ*. 2000;101:2956-61.
  386. Rauch U, Fuster V, et al. Statins and Cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins. *Atherosclerosis* 2000;1153:181-9.
  387. Roque M, Fuster V., et al. Modulation of apoptosis, proliferation and p27 expression in a porcine coronary angioplasty model. *Atherosclerosis* 2000;153:315-22.
  388. Hayes R, Chesebro JH, Fuster V, et al. Antithrombotic Effects of Abciximab, *AJC* 2000;85:1167-1172.
  389. Zaman AG, Osende JI, Chesebro JH, Fuster V., et al. In Vivo Dynamic Real-time Monitoring and Quantification of Platelet-Thrombus Formation. *ATVB* 2000;20:860-865.
  390. Sharma SK, Kini A, Marmur JD, Fuster V. Cardio-protective Effect of Prior Beta-Blocker Therapy in Reducing CK-MB Elevation after Coronary Intervention. *Circulation* 2000;102:166-72.
  391. Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, Fallon JT. Coronary Composition and Macrophage Infiltration in Atherectomy Specimens from Patients with Diabetes Mellitus. *Circ*. 2000;102:2180-4.
  392. Roque M, Reis ED, Fuster V, Padurean A, Fallon JT, Taubman MB, Chesebro JH, Badimon JJ. Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty. *J Am Coll Cardiol*. 2000;36(7):2303-10.
  393. Fonseca FA, Izar MC, Fuster V, Gallo R, Padurean A, Fallon JT, Schachter EN, Chesebro JH, Badimon JJ. Chronic endothelial dysfunction after oversized coronary balloon angioplasty in pigs: a 12-week follow-up of coronary vasoreactivity in vivo and in vitro. *Atherosclerosis*. 2001;154(1):61-9.
  394. Patrono C, Collier B, Dalen JE, FitzGerald GA, Fuster V, Gent M, Hirsh J, Roth G. Platelet-active drugs : the relationships among dose, effectiveness, and side effects. *Chest*. 2001 Jan;119(1 Suppl):39S-63S.
  395. Willerson JT, Majesky MW, Fuster V. Russell Ross, PhD : Visionary Basic Scientist in Cardiovascular Medicine. *Circ*. 2001 Jan 30;103(4):478-479.
  396. Fuster V, Willerson JT. Rene G. Favaloro, MD : The Passing of a Pioneer. *Circ*.

- 2001;103(4):480-481.
397. Gombert-Maitland, M, Baran DA, Fuster V. Treatment of Congestive Heart Failure: Guidelines for the Primary Care Physician and the Heart Failure Specialist. *Arch Intern Med*. 2001 Feb 12;161(3):342-352.
398. Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. *Ann Intern Med*. 2001;134(3):224-38.
399. Osende JI, Fuster V, Lev EI, Shimbo D, Rauch U, Marmur JD, Richard M, Varon D, Badimon JJ. Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition. *Circ*. 2001;103(11):1488-91.
400. Helft G, Worthley SG, Fuster V, Zaman AG, Schechter C, Osende JI, Rodriguez OJ, Fayad ZA, Fallon JT, Badimon JJ. Atherosclerotic aortic component quantification by noninvasive magnetic resonance imaging: an in vivo study in rabbits. *J Am Coll Cardiol*. 2001;37(4):1149-54.
401. Corti R, Osende JI, Fuster V, Fayad ZA, Fallon JT, Badimon JJ. Artery dissection and arterial thrombus aging: the role of noninvasive magnetic resonance imaging. *Circ*. 2001;103(19):2420-1.
402. Worthley SG, Osende JI, Helft G, Badimon JJ, Fuster V. Coronary artery disease: pathogenesis and acute coronary syndromes. *Mt Sinai J Med*. 2001;68(3):167-81.
403. Roque M, Reis ED, Cordon-Cardo C, Taubman MB, Fallon JT, Fuster V, Badimon JJ. Effect of p27 deficiency and rapamycin on intimal hyperplasia: in vivo and in vitro studies using a p27 knockout mouse model. *Lab Invest*. 2001;81(6):895-903.
404. Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association. *Circ*. 2001;103(24):2994-3018 and *Arterioscler Thromb Vasc Biol*. 2001;21(7):1094-6.
405. Alexander KP, Newby LK, Hellkamp AS, Harrington RA, Peterson ED, Kopecky S, Langer A, O'Gara P, O'Connor CM, Daly RN, Califf RM, Khan S, Fuster V. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. *J Am Coll Cardiol*. 2001;38(1):1-7.
406. Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to anticoagulant therapy: heparin : a statement for healthcare professionals from the American Heart Association. *Arterioscler Thromb Vasc Biol*. 2001;21(7):E9-9.
407. Corti R, Fayad ZA, Fuster V, Worthley SG, Helft G, Chesebro J, Mercuri M, Badimon JJ. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. *Circ*. 2001;104(3):249-52.
408. Fayad ZA, Fuster V. The human high-risk plaque and its detection by magnetic resonance imaging. *Am J Cardiol*. 2001;88(2-A):42E-45E.
409. Fayad ZA, Fuster V. Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. *Circ Res*. 2001 Aug 17;89(4):305-16.
410. O'Connor CM, Gattis WA, Hellkamp AS, Langer A, Larsen RL, Harrington RA, Berkowitz SD, O'Gara PT, Kopecky SL, Gheorghide M, Daly R, Califf RM, Fuster V. Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS). *Am J Cardiol*. 2001 Sep 88(5):541-6.
411. Smith SC Jr., Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, Fuster V, Gotto A, Grundy SM, Miller NH, Jacobs A, Jones D, Krauss RM, Mosca L, Ockene I,

- Pasternak RC, Pearson T, Pfeffer MA, Starke RD, Taubert K. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. *Circ*. 2001;104(13):1577-9.
412. Vorchheimer DA, Fuster V. Inflammatory markers in coronary artery disease: let prevention douse the flames. *JAMA*. 2001;286(17):2154-6.
  413. Donahue M, Fuster V., Califf RM. Results of Expert Meetings: Obesity and Cardiovascular Disease. Introduction: Cardiologists should target obesity. *Am Heart J*. 2001;142(6):1088-90.
  414. Rao SV, Donahue M, Pi-Sunyer FX, Fuster V. Results of Expert Meetings: Obesity and Cardiovascular Disease. Obesity as a risk factor in coronary artery disease. *Am Heart J*. 2001;142(6):1102-7.
  415. Fuster V, Charlton P, Boyd A. Clinical protocol. A phase IIb, randomized, multicenter, double-blind study of the efficacy and safety of Trinam (EG004) in stenosis prevention at the graft-vein anastomosis site in dialysis patients. *Hum Gene Ther*. 2001;12(16):2025-7.
  416. Fuster V, Ryden LE, Asinger RW, Cannon DS, Crijns HJ, Frye RL, Halperin, JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. *Circ*. 2001;104(17):2118-50.
  417. Osende JL, Badimon JJ, Fuster V, Herson P, Rabito P, Vidhun R, Zaman A, Rodriguez OJ, Lev EI, Rauch U, Helft G, Fallon JT, Crandall JP. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. *J Am Coll Cardiol*. 2001;38(5):1307-12.
  418. Worthley SG, Helft G, Fayad ZA, Fuster V, Rodriguez OJ, Zaman AG, Badimon JJ. Cardiac gated breath-hold black blood MRI of the coronary artery wall: an in vivo and ex vivo comparison. *Int J Card Imaging*. 2001;17(3):195-201.
  419. Corti R, Fuster V, Badimon JJ, Hutter R, Fayad ZA. New understanding of atherosclerosis (clinically and experimentally) with evolving MRI technology in vivo. *Ann N Y Acad Sci*;947:181-95; discussion 195-8.
  420. Shimbo D, Child J, Davidson K, Geer E, Osende JI, Reddy S, Dronge A, Fuster V, Badimon JJ. Exaggerated serotonin-mediated platelet reactivity as a possible link in depression and acute coronary syndromes. *Am J Cardiol*. 2002;89(3):331-3.
  421. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, GAniats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Jacobs AK, Hiratzka LF, Russel RO, Smith SC. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. *J Heart Lung Transplant*. 2002;21(2):189-203.
  422. Corti R, Osende JI, Fayad ZA, Fallon JT, Fuster V, et.al. In vivo noninvasive detection and age definition of arterial thrombus by MRI. *J Am Coll Cardiol*. 2002;39(8):1366-73.
  423. Fuster V. Applied cardiological research. Challenges for the new millennium. *Rev Esp Cardiol*. 2002;55(4):327-32. Spanish.

424. Redberg RF, Greenland P, Fuster V, et.al. Prevention Conference VI: Diabetes and Cardiovascular Disease: risk assessment in persons with diabetes. *Circ.* 2002;105(18):e144-52.
425. Choudhury RP, Aguinaldo JG, Rong JX, Kulak JL, Kulak AR, Reis ED, Fallon JT, Fuster V, Fisher EA, Fayad ZA. Atherosclerotic lesions in genetically modified mice quantified in vivo by non-invasive high-resolution magnetic resonance microscopy. *Atherosclerosis.* 2002;162(2):315-21.
426. Moreno, PR, Purushothaman KR, Fuster V, O'Connor WN. Intimomedial interface damage and adventitial inflammation is increased beneath disrupted atherosclerosis in the aorta: implications for plaque vulnerability. *Circ.* 2002;105(21):2504-11.
427. Borreguero LJ, Corti R, de Soria RF, Osende JI, Fuster V, Badimon JJ. Images in cardiovascular medicine. Diagnosis of isolated noncompaction of the myocardium by magnetic resonance imaging. *Circ.* 2002;105(21):E177-8.
428. Halperin JL, Fuster V. Patent foramen ovale and recurrent stroke: another paradoxical twist. *Circ.* 2002 ;105(22):2580-2.
429. Fuster V, Rosenbluth A. Aortic valve disease etiology and the role of vascular pathology: is the face of the disease changing? *Adv Cardiol.* 2002;39:25-38.
430. Merz CN, Mensah GA, Fuster V, et.al. The role of cardiovascular specialists as leaders in prevention: from training to champion. 33<sup>rd</sup> Bethesda Conference. *J Am Coll Cardiol.* 2002;40(4):641-51.
431. Strain J, Karim A, Caliendo G, Alexis J, Sandlin Lowe R, Fuster V. Cardiac drug-psychotropic drug update small star, filled. *Gen Hosp Psychiatry.* 2002;24(5):283.
432. Corti R, Wyttenbach R, Alerci M, Badimon JJ, Fuster V, Gallino A. Images in cardiovascular medicine. Effect of percutaneous transluminal angioplasty on severely stenotic femoral lesions: in vivo demonstration by noninvasive magnetic resonance imaging. *Circ.* 2002;106(12):1570-1.
433. Fayad ZA, Fuster V, Nikolaou K, Becker C. Computed tomography and magnetic resonance imaging for noninvasive coronary angiography and plaque imaging: current and potential future concepts. *Circ.* 2002;106(15):2026-34.
434. Badimon JJ, Fuster V. Can we image the "active" thrombus? *Arterioscler Thromb Vasc Biol.* 2002;22(11):1753-4.
435. Shimbo D, Osende J, Chen J, Robbins J, Shimoto Y, Kunitada S, Fuster V, Badimon JJ. Antithrombotic Effects of DX-9065a, a Direct Factor Xa Inhibitor. *Thromb Haemost.* 2002;88(5):733-8.
436. Corti R, Fuster V, et.al. Lipid Lowering By Simvastatin Induces Regression of Human Atherosclerotic Lesions: 2 Years Follow-Up By High-Resolution Noninvasive MRI. *Circ.* 2002;106:2884-87.
437. Fayad ZA, Fuster V. Atherothrombotic plaques and the need for imaging. *Neuroimaging Clin N Am.* 2002;12(3):351-64.
438. Doshi SN, Kim MC, Sharma SK, Fuster V. Images in cardiovascular medicine. Right and left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. *Circ.* 2002;106(2):e3-4.
439. Choudhury RP, Fuster V, et.al. MRI and characterization of atherosclerotic plaque: emerging applications and molecular imaging. *Arterioscler Thromb Vasc Biol.* 2002;22(7):1065-74.
440. Vorchheimer DA, Fuster V. Thrombin inhibitors in acute coronary artery disease. *Eur Heart J.* 2002;23(15):1142-4.
441. Fuster V, Corti R, Badimon JJ. The Mikamo Lecture 2002. Therapeutic targets for the



- treatment of atherothrombosis in the new millennium clinical frontiers in atherosclerosis research. *Circ J*. 2002;66(9):783-9
442. Poon M, Badimon JJ, Fuster V. Overcoming restenosis with sirolimus: from alphabet soup to clinical reality. *Lancet*. 2002;359(9306):619-22.
  443. Worthley SG, Helft G, Fuster V, et.al. A novel nonobstructive intravascular MRI coil: in vivo imaging of experimental atherosclerosis. *Arterioscler Thromb Vasc Biol*. 2003;23(2):346-50.
  444. Rastegar R, Harnick DJ, Weidemann P, Fuster V, et.al. ME. Spontaneous echo contrast videodensity is flow-related and is dependent on the relative concentrations of fibrinogen and red blood cells. *J Am Coll Cardiol*. 2003;41(4):603-10.
  445. Sambola A, Osende J, Hathcock J, Degen M, Nemerson Y, Fuster V, Crandall J, Badimon JJ. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. *Circulation*. 2003;107(7):973-7.
  446. Chesebro JH, Fuster V, Pugo FJ. Aspirin and mortality from coronary bypass surgery. *N Engl J Med*. 2003 ;348(11):1057-9.
  447. Corti R, Fuster V, Badimon JJ. Pathogenetic concepts of acute coronary syndromes. *J Am Coll Cardiol*. 2003 ;41(4 Suppl S):7S-14S.
  448. Hutter R, Sauter BV, Reis ED, Roque M, Vorchheimer D, Carrick FE, Fallon JT, Fuster V, Badimon JJ. Decreased reendothelialization and increased neointima formation with endostatin overexpression in a mouse model of arterial injury. *Circulation*. 2003;107(12):1658-63.
  449. Hirsh J, Fuster V, Ansell J, Halperin JL; American Heart Association; American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. *Circulation*. 2003;107(12):1692-711 and *J Am Coll Cardiol*. 2003;41(9):1633-52.
  450. Halperin JL, Fuster V. Meeting the challenge of peripheral arterial disease. *Arch Intern Med*. 2003;163(8):877-8.
  451. Jneid H, Bhatt DL, Corti R, Badimon JJ, Fuster V, Francis GS. Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. *Arch Intern Med*. 2003;163(10):1145-53.
  452. Gombert-Maitland M, Fuster V, Fayad ZA, Badimon JJ, Corti R. Statins and plaque stability. *J Cardiovasc Risk*. 2003;10(3):161-7.
  453. MacNeill BD, Lowe HC, Takano M, Fuster V, Jang IK. Intravascular modalities for detection of vulnerable plaque: current status. *Arterioscler Thromb Vasc Biol*. 2003;23(8):1333-42.
  454. Viles-Gonzalez JF, Fuster V, Corti R, Badimon JJ. Emerging importance of HDL cholesterol in developing high-risk coronary plaques in acute coronary syndromes. *Curr Opin Cardiol*. 2003;18(4):286-94.
  455. Bayes de Luna A, Tse TF, de Figueiredo MB, Maranhao M, Voute J, Nishtar S, Fuster V, Poole-Wilson P; World Heart Federation. World Heart Day: a World Heart Federation enterprise promoting the prevention of heart disease and stroke across the world. *Circulation*. 2003;108(9):1038-40.
  456. Bauriedel G, Jabs A, Skowasch D, Hutter R, Badimon JJ, Fuster V, Welsch U, Luderitz B. Dendritic cells in neointima formation after rat carotid balloon injury: coordinated expression with anti-apoptotic Bcl-2 and HSP47 in arterial repair. *J Am Coll Cardiol*. 2003 ;42(5):930-8.
  457. Purushothaman KR, Fuster V, et.al. Neovascularization is the most powerful independent predictor for progression to disruption in high-risk atherosclerotic plaques. *J Am Coll*

- Cardiol. 2003; 41;352-3.
458. Corti R, Fuster V. New understanding, diagnosis, and prognosis of atherothrombosis and the role of imaging. *Am J Cardiol.* 2003;91(3A):17A-26A.
  459. Fuster V, Corti R, Fayad ZA, Schwitter J, Badimon JJ. Integration of vascular biology and magnetic resonance imaging in the understanding of atherothrombosis and acute coronary syndromes. *J Thromb Haemost.* 2003;1(7):1410-21.
  460. Fayad ZA, Choudhury RP, Fuster V. Magnetic resonance imaging of coronary atherosclerosis. *Curr Atheroscler Rep.* 2003;5(5):411-7.
  461. Olin JW, Fuster V. Acute aortic dissection: the need for rapid, accurate, and readily available diagnostic strategies. *Arterioscler Thromb Vasc Biol.* 2003; 23 (10): 1721-3.
  462. Maseri A, Fuster V. Is there a vulnerable plaque? *Circulation.* 2003;107(16):2068-71.
  463. Moreno P, Purushothaman K, Fuster V, et.al. Plaque Neovascularization is increased in ruptured atherosclerotic lesions of the human aorta: Implications for plaque vulnerability. *Circulation.* 2004 110(14):2032-8.
  464. Hutter, R, Valdiviezo C, Bernhard V, Sauter, Savaontaus, Chereshev I, Carrick F, Bauriedel G, Luderitz B, Fallon J, Fuster V, Badimon J, Caspase-3 and tissue-factor expression in lipid-rich plaque macrophages: Evidence for apoptosis as link between inflammation and atherothrombosis. *Circulation.* 2004 109(16); 2001-8.
  465. Corti R, Osende J, Fallon J, Fuster V, et.al. The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with Simvastatin in experimental atherosclerosis. *J Am Coll Cardiol.* 2004 43(3); 464-73
  466. Osende, J, Shimbo D, Fuster V, et.al. Antithrombotic effects of S 18886, a novel orally-active thromboxane A<sub>2</sub> Receptor Antagonist, *Journal of Thrombosis and Haemostasis.* (in press)
  467. Sirol M, Itskovich V, Mani V, Aguinaldo J, Fallon J, Misselwitz B, Weinmann H, Fuster V, et.al. Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. *Circulation.* (in press)
  468. Fuster V, Fayad Z, Corti R, Badimon J, Atherothrombosis and the high-risk plaque: Evolving Concepts (Part 1 of 2). *Annals of Int. Med.* (submitted)
  469. Fuster V, Fayad Z, Corti R, Badimon J, Atherothrombosis and the high-risk plaque: Approaches by noninvasive CT/MR imaging (Part 2 of 2). *Annals of Int. Med.* (submitted)
  470. Viles-Gonzalez J, Anand SX, Valdiviezo C, Zafar MU, Hutter R, Sanz J, Ruis T, Poon M, Fuster V, Badimon JJ. Update in atherothrombosis disease. *Mt. Sinai J Med.* 2004, 71(3); 197-208.
  471. Faxon D, Fuster V, et.al. Atherosclerotic vascular disease conference: Writing Group III: pathophysiology. *Circulation.* 2004 109(21);2617-25.
  472. Sirol M, Itskovich V, Mani V, Aguinaldo J, Fallon J, Misselwitz B, Weinmann H, Fuster V, Toussaint J, Fayad Z. Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. *Circulation* 2004 109(23); 2890-6.
  473. Schaar J, Muller J, Falk E, Virmani R, Fuster V, et. al. Terminology for high-risk and vulnerable coronary artery plaques. *Eur Heart J.* 2004 25(12); 1077-82.
  474. Hutter R, Carrick FE, Valdiviezo C, Wolinsky C, Rudge JS, Wiegand SJ, Fuster V, et. al. Vascular endothelial growth factor regulates reendothelialization and neointima formation in a mouse model of arterial injury. *Circulation* 2004 110(16): 2430-5.
  475. Viles-Gonzalez JF, Poon M, Sanz J, Rius T, Nikolaou K, Fayad ZA, Fuster V, Badimon

- JJ. In vivo 16-slice, multidetector-row computed tomography for the assessment of experimental atherosclerosis: comparison with magnetic resonance imaging and histopathology. *Circulation* 2004 110(11): 1467-72.
476. Jacobs AK, Lindsay BD, Bellande BJ, Fonarow GC, Nishimura RA, Shah PM, Annex BH, Fuster V, et. al. Task force 3: Disclosure of relationships with commercial interests: policy for education activities and publications. *J Am Coll Cardiol* 2004 44(8): 1736-40.
477. Viles-Gonzalez JF, Choi BG, Fuster V, Badimon JJ. Peroxisome proliferator-activated receptor ligands in atherosclerosis. *Expert Opin Investig Drugs* 2004 13(11): 1393-403.
478. Fuster V. Oral Antithrombins and the future of antithrombotic therapy. *Rev Esp Cardiol* 2004 57(Supl. 1): 2-8.
479. Choudhury RP, Fuster V, Fayad ZA. Molecular, cellular and functional imaging of atherothrombosis. *Nat Rev Drug Disc* 2004 3(11): 913-25.
480. Danik S, Fuster V. Anticoagulation in pregnant women with prosthetic heart valves. *Mt. Sinai J Med* 2004 71(5):322-9.
481. Sanz J, Rius T, Kuschnir P, Macaluso F, Fuster V, Poon M. Images in cardiovascular medicine. Double-chambered left ventricle: complete characterization by cardiac magnetic resonance and multidetector-row computed tomography. *Circulation* 2004 110(20): e502-3.
482. Corti R, Fuster V. Should standard medical therapy for angina include a statin? *Clin Cardiol* 2004 27(10): 547-51.
483. Viles-Gonzalez JF, Gaztanaga J, Zafar UM, Fuster V, Badimon JJ. Clinical and experimental experience with factor Xa inhibitors. *Am J Cardiovasc Drugs* 2004 4(6):379-84.
484. Dayal R, Mousa A, Bernheim J, Hollenbeck S, Henderson P, Prince M, Gordon R, Badimon J, Fuster V, et. al. Characterization of retrograde collateral (type II) endoleak using a new canine model. *J Vasc Surg* 2004 40(5): 985-94.
485. Moreno PR, Fuster V. The year in atherothrombosis. *J Am Coll Cardiol.* 2004 44(11): 2099-110.
486. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. *J Am Coll Cardiol.* 2004 44(12): 2293-300.
487. Viles-Gonzalez JF, Fuster V, Badimon JJ. Thrombin/inflammation paradigms: a closer look at arterial and venous thrombosis. *Am Heart J* 2005 149(1 Supl): S19-31.
488. Shimbo D, Davidson KW, Haas DC, Fuster V, Badimon JJ. Negative impact of depression on outcomes in patients with coronary artery disease: mechanisms, treatment considerations, and future directions. *J Thromb Haemost.* 2005. May;3(5):897-908.
489. Sulica R, Dinh HV, Dunskey K, Fuster V, Poon M. The acute hemodynamic effect of IV nitroglycerin and dipyridamole in patients with pulmonary arterial hypertension: comparison with IV epoprostenol. *Congest Heart Fail.* 2005 May-Jun;11(3):139-44.
490. Corti R, Fuster V, et. al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. *J Am Coll Cardiol.* 2005 Jul 5;46(1):106-12.
491. Fuster V, Kim RJ. Frontiers in cardiovascular magnetic resonance. *Circulation.* 2005 Jul 5;112(1):135-44.
492. Couturier G, Voustantiok A, Weiberger J, Fuster V. Correlation between coronary

- artery disease and aortic arch plaque thickness measured by non-invasive B-mode ultrasonography. *Atherosclerosis*. 2005 Jul 13; [Epub ahead of print]
493. Rhee JY, Trocciola SM, Dayal R, Lin S, Chaer R, Kumar N, Mousa A, Bernheim J, Christos P, Prince M, Marin ML, Gordon R, Badimon J, Fuster V, Kent KC, Faries PL. Treatment of type II endoleaks with a novel polyurethane thrombogenic foam: induction of endoleak thrombosis and elimination of intra-aneurysmal pressure in the canine model. *J Vasc Surg*. 2005 Aug;42(2):321-8.
494. Brandoa AP, Brandoa AA, Berenson GS, Fuster V. Metabolic syndrome in children and adolescents. *Arq Bras Cardiol*. 2005 Aug;85(2):79-81. Epub 2005 Aug 18.
495. Sirol M, Aguinaldo JG, Graham PB, Weisskoff R, Lauffer R, Mizsei G, Chereshev I, Fallon JT, Reis E, Fuster V, et. al. Fibrin-targeted contrast agent for improvement of in vivo acute thrombus detection with magnetic resonance imaging. *Atherosclerosis*. 2005 Sep;182(1):79-85.
496. Gehi A, Haas D, Fuster V. Primary prophylaxis with the implantable cardioverter-defibrillator: the need for improved risk stratification. *JAMA*. 2005 Aug 24;294(8):958-60.
497. Sirol M, Fuster V et. al. Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. *Circulation*. 2005 Sep 13;112(11):1594-600.
498. Fuster V. Novel cardiovascular biomarkers and implications for clinical trials. *Nat Clin Pract Cardiovasc Med*. 2006 Feb;3(2):57.
499. Winslow RD, Pinney S, Fuster V. Impact of implantable-cardioverter-defibrillator trials on clinical management of patients with heart failure. *Nat Clin Pract Cardiovasc Med*. 2006 Feb;3(2):86-93.
500. Beller GA, Bonow RO, Fuster V. ACCF 2006 Update for Training in Adult Cardiovascular Medicine (Focused Update of the 2002 COCATS 2 Training Statement): A Report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training. Introduction. *J Am Coll Cardiol*. 2006 Feb 21;47(4):894-7.
501. Fuster V, Sanz J, Viles-Gonzalez JF, Rajagopalan S. The utility of magnetic resonance imaging in cardiac tissue regeneration trials. *Nat Clin Pract Cardiovasc Med*. 2006 Mar;3 Suppl 1:S2-7.
502. Gibbons RJ, Fuster V. Therapy for patients with acute coronary syndromes--new opportunities. *N Engl J Med*. 2006 Apr 6;354(14):1524-7.
503. Corti R, Osende J, Hutter R, Viles-Gonzalez JF, Zafar U, Valdivieso C, Mizsei G, Fallon JT, Fuster V, Badimon JJ. Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: In vivo demonstration by high-resolution MRI. *Atherosclerosis*. 2006 Apr 4.
504. Moreno PR, Purushothaman KR, Sirol M, Levy AP, Fuster V. Neovascularization in human atherosclerosis. *Circulation*. 2006 May 9;113(18):2245-52.
505. Sanz J, Weeks D, Nikolaou K, Sirol M, Rius T, Rajagopalan S, Dellegrottaglie S, Strobeck J, Fuster V, Poon M. Detection of healed myocardial infarction with multidetector-row computed tomography and comparison with cardiac magnetic resonance delayed hyperenhancement. *Am J Cardiol*. 2006 Jul 15;98(2):149-55.
506. Fuster V. Cardiovascular disease and the UN millennium development goals: a serious concern. *Nat Clin Pract Cardiovasc Med*. 2006 Aug;3(8):401.
507. Fuster V, Ryden LE, Cannon DS, Crijs HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le

- Heuzy JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S; Guidelines for the Management of Patients with Atrial Fibrillation. *Eur Heart J*. 2006 Aug;27(16):1979-2030
508. Lipinski MJ, Amirbekian V, Frias JC, Aguinaldo JG, Mani V, Briley-Saebo KC, Fuster V, Fallon JT, Fisher EA, Fayad ZA. MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. *Magn Reson Med*. 2006 Sep;56(3):601-10.
509. Sirol M, Fuster V, Fayad ZA. Plaque imaging and characterization using magnetic resonance imaging: towards molecular assessment. *Curr Mol Med*. 2006 Aug;6(5):541-8.
510. Smith S, Voute J, Fuster V. Principles for national and regional guidelines on cardiovascular disease prevention. *Nat Clin Pract Cardiovasc Med*. 2006 Sep;3(9):461.
511. Danik S, Fuster V. The obstetrical patient with a prosthetic heart valve. *Obstet Gynecol Clin North Am*. 2006 Sep;33(3):481-91
512. Pucci A, Sheiban I, Formato L, Celeste A, Brscic E, Moretti C, De Bernardi A, Alberti A, Bergamasco L, Trevi G, Fuster V. In vivo coronary plaque histology in patients with stable and acute coronary syndromes Relationships with hyperlipidemic status and statin treatment. *Atherosclerosis*. 2006 Sep 11. ACC/AHA/ESC 2006
513. Levy AP, Levy JE, Kalet-Litman S, Miller-Lotan R, Levy NS, Asaf R, Guetta J, Yang C, Purushothaman KR, Fuster V, Moreno PR. Haptoglobin Genotype Is a Determinant of Iron, Lipid Peroxidation, and Macrophage Accumulation in the Atherosclerotic Plaque. *Arterioscler Thromb Vasc Biol*. 2006 Oct 26.

### Books-Editor

1. Fuster V, ed. *Diseases of the Heart (Enfermedades de Corazon)*. En el libro: *Medicina Interna Pro Farreras-Rozman*, 7a Edicion Edit Marin, Barcelona, 1972;250-402;1978 (9<sup>th</sup> edition);1982 (11<sup>th</sup> Edition).
2. Brandenburg RO, Fuster V, Giuliani ER, McGoon DC, eds. *Cardiology: Fundamentals and Practice*. St. Louis, MO: Year Book Medical Publishers; 1987;1991(2<sup>nd</sup> edition)
3. Fuster V, Verstraete M, eds. *Thrombosis in Cardiovascular Disorders*. Philadelphia, PA: W.B. Saunders Company; 1992:1-565.
4. Fuster V, Ross R, Topol EJ, eds. *Atherosclerosis and Coronary Artery Disease*. Philadelphia, PA: Lippincott-Raven; 1996:1285-1297.
5. Fuster V, ed. *Syndromes of Atherosclerosis. Correlations of Clinical Imaging and Pathology*. Armonk, NY: Futura Publishing; 1996:1-558.
6. Fuster V, ed. *The Vulnerable Atherosclerotic Plaque: Understanding, Identification and Modification*. Armonk, NY: Futura Publishing Company, Inc.; 1998.
7. Verstraete M, Fuster V, Topol EJ, eds. *Cardiovascular Thrombosis*. Philadelphia, PA: Lippincott-Raven; 1998:1-871.
8. Nash IS, Fuster V, eds. *Efficacy of Myocardial Infarction Therapy-An Evaluation of Clinical Trials Evidence*. New York: Marcel Dekker; 1999:1-493.
9. Fuster V, Alexander RW, O'Rourke R, eds. *Hurst's the Heart*. 10<sup>th</sup> Edition. New York: McGraw Hill; 2001:1-2567.
10. Fuster V, ed., *Assessing and Modifying the Vulnerable Atherosclerotic Plaque*. Armonk, NY: Futura Publishing Company, Inc.; 2002:1-379.

11. Gresele P, Page C, Fuster V, Vermylen J. *Platelets in Thrombotic and Non-Thrombotic Disorders*. United Kingdom: Cambridge University Press;2002.
12. Kukin M, Fuster V., eds. *Oxidative Stress and Cardiac Failure*. Armonk, New York: Futura Publishing Company, Inc.;2003:1-291.
13. Lardo A.C., Fayad Z.A., Fuster V., Chronos N.A. *Cardiovascular Magnetic Resonance: Established and Emerging Applications*. London: Martin Dunitz; 2003.
14. Fuster V, Alexander RW, O'Rourke R, eds. *Hurst's the Heart*. 11<sup>th</sup> Edition. New York: McGraw Hill; 2004.
15. Fuster V, Topol E, Nabel, E, eds. *Atherothrombosis and Coronary Artery Disease*. 2<sup>nd</sup> Edition Philadelphia, PA: Lippincott-Raven; 2004.
16. Viles-Gonzalez J, Badimon J, Fuster V. Pathogenesis of Atherosclerosis (chapter 3). *Antioxidants and Cardiovascular Disease*. 2<sup>nd</sup> Edition, Montreal Canada. Springer 2006.

**Invited Articles (not displayed) – 476**  
**Abstracts (not displayed) – 492**